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ABSTRACT 
Schizophrenia is a lifelong debilitating illness requiring extended treatment with 
antipsychotic agents. A novel atypical antipsychotic agent like olanzapine is required for a 
longer period of time to prevent relapses. Non-adherence to therapy is a very common 
and severe problem in these patients. Adherence to therapy can be improved by 
prescribing depot injectable or implant formulations in such patients to significantly 
reduce the dosage frequency. The purpose of this study was to develop  Poly-(lactic-co-
glycolic acid) (PLGA) based microsphere, Poly(N-isopropylacrylamide-co-acrylic acid) 
(PNA) microgels based in situ gelling system, PLGA based in situ gel and PLGA based 
implant formulations aimed to release the olanzapine for a period of one month or more. 
These dosage forms will result in increase compliance and reduce dosage frequency. 
Reverse phase HPLC method was also developed for in vivo studies and pharmacokinetic 
assessment of these dosage forms. Microspheres loaded with olanzapine were prepared 
using oil in water emulsion and solvent evaporation technique. The microspheres were 
characterized by surface morphology, shape, size, bulk density, encapsulation efficiency 
and Fourier transform infrared spectrometry. Olanzapine loaded PNA microgels were 
prepared and characterized by viscosity measurements, cytotoxicity assay and TEM 
analysis. In vitro release of olanzapine from PNA microgels was determined on different 
pH and temperature range. PLGA based in situ gel implant was developed on the 
principle of solvent exchange. Surgically implantable olanzapine loaded PLGA cylinders 
were prepared by using solvent extrusion method. Implant formulations were 
characterized by surface morphological studies, x-ray diffractometric analysis, fourier 
transform infrared spectrometry and differential scanning calorimetric analysis. All 
formulations were evaluated for in vitro release studies. For quantification of olanzapine 
in micro-sample rat plasma, a sensitive and validated RP-HPLC method using UV 
detection was developed. HPLC method was validated for precision accuracy using limits 
of FDA’s guidance for bioanalyitcal assay validation. In vivo studies for selected 
formulations were performed on Sprague-Dawley rats. Morphological results indicated 
that microspheres produced were having smooth surface and spherical shape. The size of 
microspheres was in the range from 9.71 to 19.90 µm in mean diameter with good 
encapsulation efficiency. In vitro release of olanzapine from PLGA 50:50 microspheres 
was fastest whereas release from PLGA 85:15 microspheres was slowest of all. In vitro 
release kinetics revealed that release of drug from olanzapine PLGA microspheres is by 
 
xxi 
 
both non-fickian diffusion and erosion of PLGA polymer. Olanzapine loaded PNA 
microgels were successfully prepared with drug loading efficiency of 2.14 ± 0.52 % and 
in vitro release was characterized by a high initial burst release up to 38.6% of the drug 
release within two hours. PLGA based in situ gel implant was successfully developed on 
the principle of solvent exchange and in vitro release profiles indicate an initial burst 
release from all formulation. All formulations of PLGA surgical implant showed a tri-
phase in vitro release pattern. A reverse phase chromatographic column C18 hypersil-
BDS was used for chromatographic separation with mobile phase consisting of 50mM 
phosphate buffer pH 5.5, acetonitrile and methanol (50:30:20 v/v/v) pumped at flow rate 
of 1.2 mL/min. Olanzapine was measured using UV detection at 214 nm with retention 
time of 5.0 min. Excellent linearity with concentration range 1-500 ng/mL in rat plasma 
was obtained with coefficient of regression i.e. r
2
 =0.9986. In vivo data for microspheres 
indicated an initial burst release and then sustained release depending on ratio of lactic to 
glycolic acid in copolymer PLGA, microsphere size and bulk density. Plasma 
concentration data for in situ gelling system shows an initial burst release for all selected 
formulations as expected from in vitro data. In vivo release studies of PLGA implant 
showed that the initial release at 11 day for 50:50, 65:35, 75:25 and 85:15 PLGA based 
implant was 8.9, 7.32, 6.19 and 3.25%, respectively. The study concluded that PLGA 
microspheres and PLGA based in situ gel can be potential candidates for 30 day depot 
injection drug delivery of olanzapine in treatment of non compliant schizophrenia 
patients. PNA microgels showed a very high initial burst release which may lead to 
toxicity. Olanzapine loaded PLGA based surgically implantable cylinders provided a 
sustained of olanzapine for more than 70 days.  
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1.1 INTRODUCTION 
Schizophrenia is a chronic psychosis causing lifelong debilitating illness associated with 
devastating health, economical and social problems. It affects millions of peoples 
worldwide and treatment costs are amounting in billions of dollars annually (Piccinelli 
and Homen, 1997). Schizophrenia is one of the top ten leading causes of severe disability 
in mankind and requires a lifelong treatment with antipsychotics (Organization, 1992). 
Schizophrenia is characterized by cycles of psychosis relapse and remission which 
requires a long term treatment of antipsychotics for prevention of relapses (Gilbert et al., 
1995). Guidelines for the treatment of schizophrenia recommend strict adherence to 
antipsychotic therapy for at least one year after remission of relapse (Gilbert et al., 1995). 
Discontinuation of therapy is very common phenomenon in patients suffering from 
schizophrenia which leads to frequent relapses and psychiatric emergencies (Shen and 
Burgess, 2012). Extensive research on developing new treatments for schizophrenia has 
been done while resistance to treatment can be corrected by improving the adherence of 
antipsychotic medications (Fenton et al., 1997). Poor adherence with medications is 
found in almost 50% of schizophrenic patients which is big hurdle in achieving 
satisfactory treatment outcomes (Kane, 2005; Young et al., 1986). Nonadherance to 
antipsychotic agents can lead to frequent relapses, decreased mental and functional 
capacity, rehospitalization and inability to maintain relationships in schizophrenic patients 
(Rabin et al., 2008). 
Adherence in schizophrenic patients can be enhanced by administering the dosage forms 
which require less dosing frequency such as depot injectable. Depot parenteral 
formulations reduce the morbidity and mortality in schizophrenic patients (Kane et al., 
2003). Parenteral depot formulations have the advantages of increased bioavailability, less 
dose requirement, steady state serum concentration and reduced side effects (Siegel et al., 
2001; Gerlach, 1995). 
Olanzapine is one of the atypical second generation antipsychotic agents, which have 
been successfully employed in the treatment of schizophrenia. Olanzapine is a 
thienobenzodiazipine derivative having affinity with dopamine D1 and D2, muscarinic 
and serotonin 5HT2 receptors. Olanzapine provides an affective relief from negative and 
positive symptoms of schizophrenia with minimal extrapyramydal symptoms (Littrell and 
Littrell, 1997). 
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Biodegradable polymers have been used widely in drug delivery because of its 
biocompatible nature and ability of being metabolized by normal metabolic pathways 
without producing toxic metabolites ( lanco-Pr  Eto et al., 2000). Among biodegradable 
polymers, copolymer of lactic acid and glycolic acid (PLGA) is well known and widely 
used polymer for drug delivery. PLGA has been employed as drug carrier for variety of 
drugs ranging from small molecules to large biomolecules like proteins and vaccines 
(Burgess and Wright, 2012). PLGA has been also approved as drug carrier by US Food 
and Drug Administration (FDA) for parenteral administration as there are several FDA 
approved products containing PLGA are available in market (Perrin and English, 1997). 
Degradation rates of PLGA and drug release is dependent on the molecular weight of 
polymer and the ratio of lactic to glycolic acid in the copolymer (Alexis, 2005). Parenteral 
dosage forms based on PLGA microspheres have been well established to provide the 
desired release of drug from delivery system which can be from days to several months 
(Kostanski et al., 2000). PLGA based microsphere parentral formulations provide the 
advantages of  less frequent dosing, improved compliance, predictable release and fewer 
side effects (Cheng et al., 1998). 
Many formulations have been developed for depot injections but in situ gelling systems 
have got considerable interest because of their ease of preparation. In situ gelling systems 
are administered in the form of solution and once they are injected into tissue they form a 
semisolid gel depot (Lambert and Peck, 1995). These formulation undergo sol-gel 
transition due to one or more  gelling factors and these gelling stimuli factors include 
change in pH and temperature, ion activation and solvent exchange (Xiong et al., 2011; 
Gupta et al., 2010; Graham et al., 1999). Solvent exchange or phase sensitive in situ 
gelling systems have great potential in controlled and targeted delivery of drugs (Hatefi 
and Amsden, 2002). 
Long term solid implantable drug delivery has several advantages over the depot injection 
formulations in enhancing the adherence. Depot parenteral injections suffer from 
problems like treatment irreversibility which can be eliminated by using implantable drug 
devices, which can be removed easily at any time during treatment. Depot injection also 
cause pain at injection site thereby reduce adherence (Bloch et al., 2001). No such 
surgically implantable device for olanzapine has been reported to our knowledge. The aim 
was to enhance the adherence of schizophrenic patients towards therapy with olanzapine 
by significantly reducing the dosage frequency and side effects.  
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In situ gelling systems have gained a considerable attention in the field of biomedical 
applications (Van Tomme et al., 2008; Packhaeuser et al., 2004). As compared to surgical 
implantable depot drug delivery systems, they can provide more convenient 
administration through a syringe and can fill any shape in situ (Liang et al., 2010). 
Microgels have attracted attention in recent year as in situ gelling system for biomedical 
application (Khan, 2007). Microgels are hydrogels in colloidal size range and consisted of 
cross-linked polymers. Microgels are in situ gelling systems, which response to various 
stimuli present in situ e.g. solvent composition, pH of dispersion medium, temperature of 
medium, ionic strength and osmotic pressure (Bradley et al., 2005). Microgels in 
concentrated dispersion show a better phase transition behavior as compared to linear 
polymers, as small sized microgels combine to form a larger network of gel (Romeo et 
al., 2010; Mohanty and Richtering, 2008; Han and Bae, 1998). A dual temperature/pH 
responsive microgels based on Poly(N-isopropylacrylamide-co-acrylic acid) (PNA) were 
prepared according to previously developed and optimized method (Xiong et al., 2011). 
PNA microgels based in situ gelling system was applied for depot injection drug delivery 
of olanzapine.  
Analysis of olanzapine from biological samples is widely done by high performance 
liquid chromatography (HPLC). Previous studies have reported several HPLC analysis 
methods employing electrochemical, amperometric, ultraviolet and mass spectroscopic 
detection (Bogusz et al., 1999; Olesen and Linnet, 1998; Aravagiri et al., 1997; Chiu and 
Franklin, 1996; Catlow et al., 1995). This HPLC method employs ultraviolet detection for 
analysis which is convenient, affordable, easily available and requiring less maintenance 
as compared to other detection methods. Current method was applied to micro-sample rat 
plasma because minimal amount of blood can be withdrawn for a small animal like rat for 
repeated blood sampling.  Current method does not employ a solid phase extraction but 
still provides a desired recovery and sensitivity of assay with liquid-liquid extraction 
procedure. 
In vivo animal studies were conducted on male Sprague-Dawley rats. The rats were 
provided with free access to food and water before and during the sampling. 
Pharmacokinetic parameters for olanzapine loaded formulations in rat plasma were 
calculated by using software Thermo Kinetica 5.0 (Thermo Fisher Scientific, USA). 
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The study concluded that PLGA microspheres and PLGA based in situ gel can be 
potential candidates for 30 day depot injection drug delivery of olanzapine in the 
treatment of non compliant schizophrenia patients. PNA microgels showed a very high 
initial burst release which may lead to toxicity. Olanzapine loaded PLGA based surgically 
implantable cylinders provided a sustained of olanzapine for more than 70 days. 
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2.1 Schizophrenia 
Schizophrenia is a chronic psychosis causing lifelong debilitating illness associated with 
devastating health, economical and social problems. Schizophrenia is a severe mental 
illness characterized by heterogeneous conditions including disorganized, dysphoric, 
negative and positive symptoms (Am.Psych.Associa, 2006; Tollefson et al., 1997). 
Schizophrenia is one of the leading causes of severe disability effecting about 0.6% of 
world population (Goldner et al., 2002). It affects millions of peoples worldwide and 
treatment costs are amounting in billions of dollars annually (Piccinelli and Homen, 
1997). Patients with schizophrenia have a strong tendency for suicide and life expectancy 
is also significantly reduced (Newman and Bland, 1991). Schizophrenia is characterized 
by cycles of psychosis relapse and remission which requires a long term treatment of 
antipsychotics for prevention of relapses (Gilbert et al., 1995). 
2.1.1 Course of illness for schizophrenia 
Schizophrenic patients have a highly variable course illness and complete remission is 
highly unlikely (Ciompi, 1980; Huber et al., 1980). Only 20-30% of the patients can live 
a normal life but with some limitations. Severity of the acute episodic symptoms may 
reduce with age but negative symptoms of the disease become more prominent 
(Mcglashan and Fenton, 1993).  Characteristic symptoms of schizophrenia are shown in 
Table 2.1. 
2.1.2 Treatment of schizophrenia 
There is no cure available for the chronic debilitating disease like schizophrenia but 
medication therapy can certainly reduce the symptoms of the patients and improve the 
quality of life. Most of the patients require a lifelong treatment with medications. Other 
interventions for the treatment includes, psychosocial training and rehabilitation care 
process (Koda-Kimble et al., 2012). 
2.1.2.1 Treatment in acute phase 
Treatment with antipsychotic agents should be immediately started on observation of 
symptoms, as it will slow down the course of episode of illness. Non-pharmacological 
interventions should also be initiated with pharmacotherapy (Wyatt, 1991).  
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2.1.2.2 Treatment in stabilization phase 
As symptoms of acute start to reduce the patient enters into a stabilization phase. During 
stabilization phase, major aim is to prevent the further relapses of the disease. 
Antipsychotics prescribed in acute phase should be continued in stabilization phase for at 
least six months. The treatment should include both pharmacological and non-
pharmacological therapies, which will provide a gradual improvement in the course of 
disease (Robinson et al., 1999b). Positive and negative symptoms of schizophrenia are 
summarized in Table 2.1. 
 
Table 2.1 Description of symptoms related with schizophrenia 
Positive Negative 
Combativeness, agitation, and hostility Psychomotor retardation affective 
flattening 
Tension Avolition 
Hyperactivity Lack of socialization 
Hallucinations Alogia 
Delusions Loss of emotional connectedness 
Disorganized speech (loose associations, tangential, 
blocking) 
Loss of executive functions 
Unusual behavior  
From reference: (Koda-Kimble et al., 2012) 
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2.2 Atypical Antipsychotics 
Atypical antipsychotics can be described as drugs producing antipsychotic effects with 
minimal extrapyramidal symptoms on normal treatment doses (Meltzer, 2000). Atypical 
antipsychotic drugs are very potent antagonists of 5-HT2A receptors, but in comparison 
having a low antagonistic effect on D2 receptors (Meltzer and Huang, 2008). Less 
intensity in blockade of D2 receptors than of 5-HT2A receptors is responsible of less 
extrapyramidal symptoms. Another benefit of less intense D2 receptor binding is less 
elevation in serum prolactin levels than typical antipsychotics (Haddad and Wieck, 2004). 
Elevated serum prolactin levels can lead to galactorrhea, osteoporosis, breast cancer and 
dysphoria (Bushe et al., 2008). Atypical antipsychotic have been found more effective 
than typical antipsychotics in treatment of treatment-resistant schizophrenia (Meltzer, 
1997; Kane et al., 1988). The atypical antipsychotics have the advantage of reducing the 
risk of developing violence, aggression, tardive dyskinesia (TD) and psychosis, when 
compared with typical antipsychotics (Kane et al., 1988). Efficacy and tolerability of 
atypical antipsychotics make them a preferred choice over typical antipsychotics in 
treatment of schizophrenia. Comparative Receptor affinity for typical and atypical 
antipsychotic drugs is shown in Table 2.2. 
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Table 2.2 Comparative Receptor affinities for typical and atypical antipsychotic 
drugs 
Receptor D1 D2 5-HT2 α1 M1 H1 
Typical Agents 
Chlorpromazine - +++ ++ +++ +++ ++ 
Fluphenazine - +++ + + - - 
Perphenazine - +++ ++ ++ - ++ 
Thioridazine + +++ ++ +++ +++ + 
Haloperidol 
++ +++ + + - - 
Atypical Agents 
Clozapine ++ ++ +++ +++ +++ + 
Risperidone - +++ +++ +++ - + 
Olanzapine ++ ++ +++ ++ +++ ++ 
Quetiapine - + ++ +++ + + 
Ziprasidone 
± ++ +++ ++ - + 
Aripiprazole 
+ +++ ++ ++ - + 
Paliperidone - +++ +++ +++ - + 
Compiled from references: (Koda-Kimble et al., 2012; Burns, 2001; Bench et al., 1996) 
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2.3 Olanzapine 
Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H thieno[2,3][1,5]benzodiazepine) is 
a thienobenzodiazipine derivative (Figure 2.1), which is an atypical antipsychotic 
effectively used in the treatment of schizophrenia and bipolar disorders (Scherk et al., 
2007; Moore et al., 1993).  Olanzapine was introduced as novel antipsychotic which is 
categorized as atypical antipsychotic having more efficacy and better safety profile as 
compared to conventional antipsychotics like haloperidol (Tollefson et al., 1997). 
Olanzapine has shown to have affinity with dopamine D1 and D2, muscarinic and 
serotonin 5HT2 receptors (Van Der Zwaal et al., 2008). Olanzapine provides an affective 
relief from negative and positive symptoms of schizophrenia with minimal 
extrapyramydal symptoms (Littrell and Littrell, 1997). Plasma concentration of 
olanzapine has a correlation with its clinical effects and also shown to have individual 
variability in its pharmacokinetics (Perry et al., 1997; Preskorn et al., 1993). Many drug 
interactions with olanzapine have also shown to change the pharmacokinetics of 
olanzapine (Olesen and Linnet, 1999). Olanzapine is considered as innovative drug entity 
and widely used in about four million patients around the world, due to its safety and 
efficacy profile (Tollefson and Taylor, 2000). 
2.3.1 Physicochemical properties 
Olanzapine is yellow crystalline or light yellow crystalline powder which is practically 
insoluble in water and soluble in n-Propanol. The pKa value for olanzapine is 5.00 and 
7.40 in Dimethylformamide/Water (60:40, v/v). Melting point of olanzapine powder is 
195 ± 2°C. 
2.3.2 Pharmacokinetics of olanzapine 
Half life of olanzapine is variable, which ranged from 21-54 hours. The apparent 
clearance from plasma is 12- 47 liters/hours with mean of 26 liters/hour. Olanzapine is 
highly metabolized with first pass effect and only 60% of the dose reaches the systemic 
circulation. Protein binding of olanzapine is 93% and about 90% of the drug is bound to 
albumin. Olanzapine is both excreted in urine and faeces with 60% and 30% excretion, 
respectively (Callaghan et al., 1999).  
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Figure 2.1 Chemical structure of olanzapine 
 
2.4 Poly(lactide-co-glycolide) 
Biodegradable polymers have been used widely in drug delivery systems because of their 
biocompatible nature and ability of being metabolized by normal metabolic pathways 
without producing toxic metabolites ( lanco-Pr  Eto et al., 2000). Among biodegradable 
polymers, poly-(d,l-lactic-co-glycolide) (PLGA) is one of the widely used synthetic 
biodegradable polymer for drug delivery because of its better biocompatibility and 
excellent biodegradability (Jain, 2000). PLGA has been employed as drug carrier for 
variety of drugs ranging from small molecules to large biomolecules like proteins and 
vaccines (Burgess and Wright, 2012). PLGA has been also approved as drug carrier by 
US Food and Drug Administration (FDA) for parenteral administration as there are 
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several FDA approved products containing PLGA are available in market (Perrin and 
English, 1997). Degradation rates of PLGA and drug release is dependent on the 
molecular weight of the polymer and the ratio lactic to glycolic acid in the copolymer 
(Alexis, 2005).  
 
 
Figure 2.2 Chemical structure of PLGA, where x and y indicates the number of times 
each unit repeats 
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2.5 Adherence to Therapy in Schizophrenia 
Non-adherence to prescribed medication is present in almost one third of the patients, 
which leads to aggravation in their symptoms (West et al., 2005; Robinson et al., 1999a). 
Cycles of psychosis and remission, functional decline and disorganized behavior are 
characteristic features of schizophrenia, which requires a long term treatment with 
antipsychotics (Tollefson and Taylor, 2000; Gilbert et al., 1995). Non cooperative 
behavior of schizophrenic patient towards adherence of therapy is presenting a big 
challenge for physician in treating this chronic psychotic disease (Nahata and Saini, 
2008). Extensive research on developing new treatments for schizophrenia has been done 
while resistance to the treatment can be corrected by improving the adherence of 
antipsychotic medications (Fenton et al., 1997). Poor adherence with medications is 
found in almost 50 % of schizophrenic patients which is big hurdle in achieving 
satisfactory treatment outcomes (Kane, 2005; Young et al., 1986). Nonadherance to 
antipsychotic agents can lead to frequent relapses, decreased mental and functional 
capacity, rehospitalization and inability to maintain relationships in schizophrenic patients 
(Rabin et al., 2008). Guidelines for the treatment of schizophrenia recommend strict 
adherence to antipsychotic therapy for at least one year after remission of relapse (Gilbert 
et al., 1995). The compliance in patients with such long term treatment schedule can be 
improved by employing the sustained release dosage forms, which significantly reduce 
dosage frequency thereby enhancing compliance. 
2.6 Depot Parenteral Drug Delivery Systems 
Sustained release drug delivery systems have been applied through various routes of 
administration. In transdermal and mucosal drug delivery, the absorption is hindered by 
permeation barriers (Prausnitz et al., 2004) and in oral rout, the systemic availability is 
affected by gastrointestinal absorption and first pass effect (Varma et al., 2010). 
Parenteral rout for drug administration e.g., intravenous, intramuscular and subcutaneous 
has the benefit of easy access to systemic circulation and rapid absorption. Rapid 
absorption of drug is also followed by rapid decline in drug levels and to alleviate this 
problem, sustained release depot parenteral preparations were introduced. Depot 
parenteral preparations have gained a considerable attention around the globe for 
sustained release of drugs (Makadia and Siegel, 2011). Many formulations have been 
developed for depot parenteral delivery of drugs e.g., microspheres, in situ gelling 
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systems, suspensions, liposomes, surgical implants, solid lipid nanoparticles (SLN) and 
lipophilic solutions (Delgado Rivera et al., 2013; Kempe and Mäder, 2012; Larsen et al., 
2008; Wissing et al., 2004; Larsen et al., 2002; Siegel et al., 2001; Sharma and Sharma, 
1997). 
As in case of schizophrenia, non cooperative behavior of schizophrenic patient towards 
adherence of therapy is presenting a big challenge for physician in treating this chronic 
psychotic disease (Nahata and Saini, 2008). Long acting injections can alleviate the 
problem of non adherence in such patients by remarkably decreasing the dosing 
frequency. For the purpose of long acting injections, many formulations have been 
developed such as halodal decanoate, olanzapine pamoate and risperidone microspheres 
(Kane et al., 2010; Bai et al., 2006; Nayak et al., 1987).  
2.6.1 Microspheres for depot parenteral drug delivery 
Microspheres are widely employed for sustained delivery of many drugs; the application 
of microspheres encompasses protein delivery, vaccine development, antpsychotic drug 
delivery, cardiovascular drug delivery, chemotherapy and hormone therapy (Cao and 
Shoichet, 1999; Burgess and Hickey, 1994; Cohen et al., 1991). Parenteral dosage forms 
based on PLGA microspheres have been well established to provide the desired release of 
drug from the delivery system which can be from days to several months (Kostanski et 
al., 2000). PLGA based microsphere parentral formulations provide the advantages of  
less frequent dosing, improved compliance, predictable release and fewer side effects 
(Cheng et al., 1998). PLGA based microspheres provide a biphasic release pattern 
consisting of diffusion and biodegradation. Biodegradation of PLGA gives a continuous 
change in release pattern of the drug whereas initial burst release is also observed due to 
loosely bound drug on the superficial regions of microspheres (Lewis, 1990). Among 
other methods used for the preparation of microspheres, solvent evaporation is one of the 
earliest, reliable and commonly used method (Freitas et al., 2005). PLGA based 
microsphere formulation of olanzapine for schizophrenia treatment have been previously 
reported (D’souza et al., 2013; Nahata and Saini, 2008). The Purpose of this study was to 
develop a new PLGA based microsphere formulation aimed to release olanzapine for the 
period of one month which will result in increase compliance and reduced dosage 
frequency. 
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2.6.2 In situ gelling systems for depot parenteral drug delivery 
Many formulations have been developed for depot injections but in situ gelling systems 
have got considerable interest because of their ease of preparation. They have gained a 
considerable attention in the field of biomedical applications (Van Tomme et al., 2008; 
Packhaeuser et al., 2004). As compared to surgical implantable depot drug delivery 
systems, they can provide more convenient administration through a syringe and can fill 
any shape in situ (Liang et al., 2010). In situ gelling systems are administered in the form 
of solution and once they are injected into tissue they form a semisolid gel depot 
(Lambert and Peck, 1995). These formulation undergo sol-gel transition due to one or 
more  gelling factors and these gelling stimuli factors include change in pH and 
temperature, ion activation and solvent exchange (Xiong et al., 2011; Gupta et al., 2010; 
Graham et al., 1999). 
2.6.2.1 PLGA based in situ gelling system 
Solvent exchange or phase sensitive in situ gelling systems have a great potential in 
controlled and targeted delivery of drugs (Hatefi and Amsden, 2002). Depot in situ gelling 
system is liquid containing a mixture of  biodegradable and hydrophobic polymer 
dissolved in biocompatible water miscible organic solvent (Dunn et al., 1999; Royals et 
al., 1999). Hydrophobic polymer solution becomes gel when it comes in contact with 
aqueous tissue environment due to phase transition (Packhaeuser et al., 2004). During 
solvent exchange or phase transition phase, the water miscible organic solvent from the 
polymer solution diffuse out in the aqueous environment of the tissue and in return water 
diffuses in the implant forming a gel like structure (Mchugh and Miller, 1995). 
 Biodegradable polymers are widely employed in preparation of in situ gelling implant 
due to their degradation in vivo through enzymatic and non-enzymatic process resulting in 
toxicologically safe byproducts (Wu, 1995). Poly(d,l-lactic-co-glycolide) (PLGA) is one 
of the widely used synthetic biodegradable polymer for drug delivery because of its better 
biocompatibility and excellent biodegradability (Jain, 2000). Controlled drug release and 
initial burst release from PLGA based in situ gel systems is directly related to the phase 
inversion rate pattern and the morphology of resultant gel system (Solorio et al., 2010). 
Many water miscible organic solvents have been employed as vehicle for polymer and 
drug e.g., triacetin, tetrahydrofuran, acetone, 2-pyrrolidone, N-methyl-2-pyrrolidone 
(NMP) and dimethyl sulfoxide (DMSO), but NMP and DMSO are more preferred 
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vehicles (Hatefi and Amsden, 2002). To our knowledge olanzapine microspheres and 
olanzapine pamoate for depot parenteral drug delivery has been previously reported 
(Nahata and Saini, 2008; Lilly, 3 January 2008), but no in situ gelling device of 
olanzapine for such purpose has been reported. The aim of this study was to prepare the 
PLGA based in situ gelling implant for sustained parenteral drug delivery of olanzapine 
for one month which could significantly decrease the dosage frequency and enhance the 
compliance of schizophrenic patients. 
2.6.2.2 PNA microgel based in situ gelling system 
Microgels have attracted attention in recent years as in situ gelling system for biomedical 
application (Khan, 2007). Microgels are hydrogels in colloidal size range and consisted of 
cross-linked polymers. Microgels are in situ gelling systems, which response to various 
stimuli present in situ e.g. solvent composition, pH of dispersion medium, temperature of 
medium, ionic strength and osmotic pressure (Bradley et al., 2005). Microgels in 
concentrated dispersion show a better phase transition behavior as compared to linear 
polymers, as small sized microgels combine to form a larger network of gel (Romeo et 
al., 2010; Mohanty and Richtering, 2008; Han and Bae, 1998). All these properties of 
microgels, make them a potential and suitable candidate as an in situ gelling system for 
drug delivery (Xiong et al., 2011).  
A dual temperature/pH responsive microgels based on Poly(N-isopropylacrylamide-co-
acrylic acid) (PNA) were prepared according to previously developed and optimized 
method (Xiong et al., 2011). PNA microgels based in situ gelling system was applied for 
depot injection drug delivery of olanzapine.  
2.6.3 PLGA based implantable depot parenteral delivery 
Parenteral depot formulations have the advantages of increased bioavailability, less dose 
requirement, steady state serum concentration and reduced side effects (Siegel et al., 
2001; Gerlach, 1995). Long term solid implantable drug delivery has several advantages 
over the depot injection formulations in enhancing the adherence. Depot parenteral 
injections suffer from problems like treatment irreversibility which can be eliminated by 
using implantable drug devices. Implanted parenteral devices can be removed easily at 
any time during treatment. Depot injection also cause pain at injection site thereby reduce 
adherence (Bloch et al., 2001). Surgically implantable PLGA devices for drug delivery 
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had been prepared by using several different methods e.g. solvent casting, melt extrusion 
and solvent extrusion (Wang et al., 2010; Desai et al., 2008; Siegel et al., 2001). 
Keeping in mind the several advantages of surgically implantable devices over depot 
parenteral injectable, we developed and evaluated a PLGA based surgically implantable 
device for olanzapine. No such surgically implantable device for olanzapine has been 
reported to our knowledge. The aim was to enhance the adherence of schizophrenic 
patients towards therapy with olanzapine by significantly reducing the dosage frequency 
and side effects. 
2.6.4 Previous work on depot parenteral delivery 
2.6.4.1 Chromatographic methods for olanzapine 
Patel et al., (2012) developed an LC-MS/MS method for determination of olanzapine in 
human plasma and applied this method by performing bioequivalence studies. Sample 
preparation was done using solid phase extraction technique. Quetiapine was used as 
internal standard, which is an antipsychotic agent. Chromatographic separations were 
done on a C18 column of 100 mm length and 4.6 mm internal diameter. Mobile phase 
consisted of acetonitrile and 2 mM ammonium formate at the ratio of 85:15% v/v with pH 
6.6. Flow rate of mobile phase was 0.9 mL per minute and total rum time was 3.5 
mininutes. The assay was validated according to FDA guidelines. Lower limit of 
quantification was 0.10 ng/mL and lower limit of detection was 0.012 ng/mL.  Accuracy 
of the assay was 97.0% to 103.1% and precision was 1.2% to 3.9% (C.V, %). All 
validation parameters of assay were found within the limits according to FDA guidelines. 
The LC-MS/MS method was successfully applied to bioequivalence studies in human 
volunteers.  
Raggi et al., (2000) reported a reverse phase high performance liquid chromatographic 
(HPLC) method for determination of olanzapine in human plasma. In this method an 
amperometric detector was applied instead of ultraviolet detector to get better sensitivity 
of assay. Chromatographic separations were performed on a reverse phase C18 column of 
150 mm length and 4.6 mm internal diameter. The mobile phase consisted of acetonitrile 
and 2.0 mM phosphate buffer in ratio 30:70 v/v at pH 2.5. Flow rate of mobile phase was 
1 mL per minute and detection voltage for amperometric detector was +900 mV. The 
samples for HPLC were prepared by solid phase extraction technique, which could 
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prepare the sample for low plasma volumes (up to 0.25 mL).  Lower limit of 
quantification was 1.4 ng/mL and lower limit of detection was 1.0 ng/mL. The accuracy 
and precision of assay was found with the acceptable range. The amperometric detection 
was also compared with ultraviolet detection for the assay of olanzapine in human 
plasma. This chromatographic method was also applied to study the pharmacokinetics of 
olanzapine in human volunteers. Interference with other central nervous system drugs 
during chromatographic separation was also evaluated for this assay. (Raggi et al., 2000) 
2.6.4.2 Microspheres for depot parenteral delivery 
Hickey et al., (2002) developed the PLGA based microspheres for parenteral depot drug 
delivery of dexamethasone. The aim of study was to develop a one month sustained 
delivery system of dexamethasone for the relief of both acute and chronic inflammatory 
reaction from implantation of biosensor devices. Microspheres were prepared with 
solvent evaporation method employing a combination of methanol and dichloromethane 
as oil phase. To further delay the drug release from microspheres, 2% of polyethylene 
glycol was added to the oil phase (w/v) during emulsification process. The resultant 
microspheres were evaluated by size analysis, electron microscopy, encapsulation 
efficiency, degradation study and in vitro release studies. Microspheres prepared with this 
method were having smooth surface with spherical shape and average size of 
microspheres was 11±1 µm as in mean diameter. Low encapsulation efficiency was 
reported for dexamethasone in microspheres. In vitro release studies were performed in 
phosphate buffer (pH 7.4) at 37°C and in vitro release from standard and predegraded 
microspheres was compared. In vitro release data showed that standard microspheres 
were having an initial burst release with one month sustained release, whereas 
predegraded microspheres were having less initial burst release but sustained release did 
not last for one month. The study recommends the use of mixed microsphere system of 
dexamethasone for better control of inflammation. (Hickey et al., 2002) Patel et al., 2012) 
Erden and Celebi (1996) studied the factors influencing the release of salbutamol from 
PLGA based microspheres. Microspheres were produced by solvent evaporation method 
using w/o/w emulsion. Multiple emulsion technique was employed to entrap the water 
soluble drug salbutamol in hydrophobic polymer PLGA. Microspheres were evaluated by 
determination of drug loading, entrapment efficiency, particle size analysis and in vitro 
release. Effect of changing drug loading, amount of gelatin and concentration of PVA on 
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microsphere size and entrapment efficiency was studied. Microspheres prepared in this 
study were having a spherical shape and smooth surface. Particle size of microspheres 
was relatively large (up to 207 µm) but still in acceptable range. Molecular weight of 
polymer PLGA had a direct relationship with the size of microspheres. In vitro release 
data indicates a biphasic release pattern of salbutamol from microspheres, characterized 
by initial burst release followed by sustained release. Initial burst release is explained by 
diffusion mechanism through pore formation in microspheres. Particle size, molecular 
weight of polymer and drug loading had a significant effect on the release of salbutamol 
from microspheres. In vitro release was not significantly affected by the size of 
microsphere. The release of salbutamol was extended to just 8 hours, which could be on 
lower side when developing an injectable depot drug delivery system. (Erden and Celebi, 1996) 
Choi et al., (2002) prepared and evaluated PLGA microspheres loaded with fentanyl. 
Microspheres were prepared by solvent evaporation technique employing water in oil 
emulsion. Ethyl acetate was used a oil phase and polyvinyl alcohol was added as 
emulsifier. Microspheres were characterized by morphological analysis, x-ray 
diffractometery and in vitro release study. Impact of changing the drug loading, polymer 
concentration and volume of oil phase used on the in vitro release of fentanyl from 
microspheres was evaluated. Microspheres were having spherical shape but smooth 
surface with few pores. Entrapment efficiency was increased as the concentration of 
PLGA added was increased. In vitro release was affected by changing the drug loading, 
polymer concentration and volume of oil phase used in emulsion. This study has provided 
a formulation of PLGA based fentanyl microspheres, which can release the drug for about 
15 days. A sensitive and validated gas chromatographic method for determination of 
fentanyl was also reported in this study. (Choi et al., 2002). 
2.6.4.3 In situ gelling system for depot parenteral delivery 
Xiong et al., (2011) developed a novel in situ gelling system for depot parentral drug 
delivery based on dual stimuli of temperature and pH. In this study a Poly(N-
isopropylacrylamide-co-acrylic acid) (PNA) based microgels were formulated and 
evaluated as in situ gelling systems. The study was aimed to overcome the problems of 
syringeability of temperature sensitive depot in situ gels by developing a dual temperature 
and pH sensitive polymer microgels. PNA microgels were prepared by using emulsion 
polymerization technique and by applying different concentrations of acrylic acid. After 
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preparation, PNA microgels were purified by dialysis and freeze dried for storage. 
Formulations were characterized by photo correlation spectroscopy, Transmission 
electron microscopy, viscosity measurements, MTT cytotoxicity analysis, sol-gel 
transition behavior and in vivo gel formation studies. Sol gel transition behavior of  PNA 
microgels on temperature/pH change stimuli was affected by amount of acrylic acid 
added, ion strength and density of the cross linker. In this study a 3D diagram for sol gel 
transition was illustrated, showing the impact of change in temperature, pH and 
concentration on highly concentrated dispersion of PNA microgels. An 8% dispersion of 
PNA microgels (10.95% acrylic acid) provided a better syringeability, as it maintained its 
liquidity at pH 5.0 and temperature range 25-40°C during syringe filling and rapidly 
convert to gel on pH 7.4 at 37°C (physiological condition). The dual stimuli nature 
prevents the problems of syringe clogging and premature gelation with only temperature 
sensitive polymers. In vitro sol gel transition was demonstrated successfully with tube 
inversion method at various pH and temperature. In vivo gel formation was successfully 
demonstrated in rats with 8% dispersion of PNA microgels. MTT cytotoxicity studies 
revealed a non toxic behavior of PNA microgels. In conclusion, PNA microgels in situ 
gelling system can be applied for depot parenteral drug delivery on the bases of its dual 
tempaerature/pH sensitive nature. (Xiong et al., 2011) 
A poly(N-isopropylacrylamide) (PNIPAAm) based temperature sensitive in situ gelling 
system was applied for the drug delivery of rhodamine B and ibuprofen by Zhang et al., 
(2010). A novel PNIPAAm microgels based in situ gelling system was prepared with two 
step preparation procedure. PNIPAAm microgels were characterized by scanning electron 
microscopy, transmission electron microscopy, differential scanning microscopy and 
swelling ratio. Loading and in vitro release of drugs from PNIPAAm microgels was also 
studied. A microstructure of PNIPAAm microgels provided a more efficient temperature 
sensitive in situ gelling system. SEM image analysis revealed a mono-dispersed and non-
aggregating nature of PNIPAAm microgels. Microgels indicated a high swelling nature at 
room temperatures but a shrinkage behavior at 37°C. Drug release from PNIPAAm 
microgels was delayed at temperature above 20°C but provided an initial burst release of 
40% and 70% for rhodamine B and ibuprofen, respectively. Initial burst release was 
followed by a more delayed release due to shrinkage of gel network. This study 
concluded that improved temperature responsive PNIPAAm microgels could be used as 
potential drug delivery systems for depot parenteral applications. (Zhang et al., 2010a) 
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Huo et al., (2006) applied a tmeprature/pH sensitive poly(N-isopropylacrylamide-co-
acrylic acid) (PNIPAM/AAc) microgels for binding of bovine albumin protein on its 
surface. Sets of formulations were prepared by altering the concentration of acrylic acid 
and cross linker added to PNIPAM/AAc microgels. Adsorption of bovine serum protein 
on PNIPAM/AAc microgels was done at various temperature and pH. The PNIPAM/AAc 
microgels were characterized by photo correlation spectroscopy and atomic force 
microscopy. Adsorption of bovine serum protein was significantly affected by change in 
temperature and pH. Maximum adsorption on PNIPAM/AAc microgels was achieved on 
pH 4.0 and a low adsorption was attained at basic pH and also on pH lower than 4.0. The 
binding of bovine serum protein to PNIPAM/AAc microgels altered the swelling and 
deswelling properties of microgels. Atomic force microscopy revealed the morphology of 
microgels, which indicates that aggregation of spherical PNIPAM/AAc microgels after 
binding with bovine serum proteins. Temperature responsiveness of PNIPAM/AAc 
microgels was also shifted towards lower temperatures on binding of bovine serum 
albumin. (Huo et al., 2006) 
Ravivarapu et al., (2000) developed a phase sensitive in situ forming implant for the 
sustained delivery of leuprolide acetate. The main aim of the study was to determine the 
effect of changing drug load on release of leuprolide from depot in situ forming parenteral 
implant. They developed the depot implant for suppressing the testosterone level for 90 
days in dogs. In this study, in situ forming depot implant was compared with commercial 
preparation of depot injectable microspheres. Formulation was prepared by dissolving 
PLGA (45% w/w) in N-methyl-2-pyrrolidone (NMP) by placing it over shaker for 
overnight. Different drug loads were evaluated for their effect on the release of drug from 
in situ forming implant. All formulations were sterilized with gamma irradiation before 
injecting into subcutaneous tissue of beagle dogs. Only in vivo release studies on beagle 
dogs was reported with respective serum testosterone levels. This study reported, there 
was no significant effect of changing drug load on the release pattern of leuprolide from 
in situ forming implant. As higher drug loads provides the benefit of less injection 
volume, therefore formulation of highest drug load (6% w/w) was reported to be 
compared with commercial product. Drug serum levels and serum testosterone 
concentration were evaluated for both test formulation and commercial formulation. 
There was no significant difference between test and commercial formulation except on 
some points of drug release but with high standard deviation. In conclusion, this study 
 
21 
 
stated that 6% drug loaded phase sensitive in situ forming implant formulation is potential 
candidate for depot injection of leuprolide acetate. The process of manufacturing was 
easy to scale up for industrial manufacturing purposes. (Ravivarapu et al., 2000) 
Hyun et al., (2007) studied methoxy poly(ethylene glycol)- Poly(caprolactone) (MPEG-
PCL) diblock copolymer for protein drug delivery application. MPEG-PCL was 
employed as biodegradable in situ gelling system for depot parenteral administration. In 
situ gel formation or phase transition was based on change in temperature. At room 
temperature the MPEG-PCL aqueous solution was in liquid form but when temperature 
changed to 37°C, the liquid formulation turned into gel form. In this study MPEG-PCL 
aqueous solution was compared with Pluronic F-127 for in vitro and in vivo studies. Both 
formulations were immediately turned into gel form when phosphate buffer based 
dissolution medium is heated to body temperature (37°C). The gel structure for Pluronic 
F-127 and MPEG-PCL was maintained for 2 days and 28 days, respectively. When these 
two solutions were applied subcutaneously to rats, the MPEG-PCL gel maintained its 
structure for 30 days as compared to Pluronic F-127 gel, which maintained its structure 
for just 2 days. These two formulations were also evaluated for albumin release in both in 
vitro and in vivo conditions. MPEG-PCL based in situ gel provided a longer (30 days) in 
vivo release of albumin than Pluronic F-127 based in situ gel (3 days). The study 
concluded that MPEG-PCL base temperature sensitive in situ gelling system is potential 
candidate for depot parenteral delivery of drugs and proteins. (Hyun et al., 2007) 
Singh and Singh (2007) developed phase sensitive biodegradable polymer based in situ 
gelling system for sustained delivery of leuprolide acetate. This in situ gelling system was 
evaluated by in vitro drug release and in vivo absorption in rabbits. In situ gelling system 
was also evaluated for its biocompatibility by MTT cytotoxicity assay. A combination of 
two organic solvents was employed instead of single solvent system. DL-Polylactic acid 
was used as biodegradable polymer, which was dissolved in mixture of benzyl benzoate 
and benzyl alcohol. Leuprolide was added to the polymer solution by homogenization. 
The solution of polymer and drug turned to gel when it is injected in aqueous release 
media. The in vitro release studies were carried on 37°C in 15 mL of phosphate buffer 
saline (pH 7.4). In vivo absorption was evaluated in rabbits by measuring the plasma 
levels of leuprolide acetate and testosterone. In vitro release of leuprolide acetate was 
accelerated when hydrophilic solvent ratio was increased in two solvents system. MTT 
assay assures the biocompatibility of the formulations. In vivo studies revealed that phase 
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sensitive in situ gelling system can release the leuprolide acetate for three months to 
suppress the testosterone concentration at castration level for three months. The study 
concluded that PLA based phase sensitive in situ gelling system can be applied for depot 
parenteral delivery of leuprolide acetate. This study suggests that more investigation can 
be performed to further increase the leuprolide acetate release up to six months. 
An in situ gelling system based on PLGA dissolved in polyethylene glycol (PEG) was 
described in U.S. Patent No. EP 2044959 A1  (Su et al., 2004). In this study, the PLGA 
was dissolved in liquid, semisolid or wax medium of PEG. Co-drug of diclofenac-
morphine ester was used as model drug. Both PLGA and co-drug were dissolved in 
PLGA by placing it on shaker for overnight. Preferably study employed 50:50 and 85:15 
grades of PLGA for dosage form development. The dosage was administered with normal 
saline. Co-drug of diclofenac-morphine ester showed a sustained release pattern upto 40 
days when formulated with 5% w/v PLGA (50:50) in PEG 400. (Singh and Singh, 2007) 
2.6.4.4 PLGA based solid implant for depot parenteral delivery 
Rabin et al., (2008) demonstrated the in vitro release and in vivo absorption studies of 
risperidone implants. The aim of the study was to reduce the non-adherence in 
schizophrenic patient by developing surgically implantable devices for the delivery of 
risperidone. Implants were developed using Poly Lactic-co-Glycolic Acid (PLGA), a 
widely used biodegradable polymer. Implants were fabricated by dissolving PLGA and 
different drug loads of risperidone in a solvent and solvent was then allowed to evaporate. 
After the solvent is completely evaporated, thin film of drug and polymer was resulted. 
This film is then either compress molded or melt extruded to manufacture solid implants. 
Solid implants were sterilized using ethylene oxide. In vitro release studies were 
performed in 500 mL of phosphate buffer saline stirred at 40 rpm on 37°C. In vivo 
release, pharmacokinetics and behavioral studies were performed on mice. In vitro release 
of risperidone from solid PLGA implants was influenced by the type of PLGA used and 
drug loads of the risperidone. Stability of risperidone was also demonstrated in PLGA 
based implants under physiological conditions. PLGA based implants with 40 % drug 
load were evaluated for pharmacokinetic studies. Pharmacokinetic data indicates that 
plasma levels of 2-15 ng/mL for risperidone were maintained for at least 56 days after 
implantation. Behavioral studies indicate that plasma levels were not reached higher than 
anticipated levels as there was no distress shown by animals. Authors suggest that scaling 
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the results from mice to human level is very complicated. In conclusion the study 
presented a potential parenteral drug delivery system, which could have the potential for 
releasing the drug over three months period. The potential carrier system was also 
demonstrated through in vitro and in vivo studies. (Rabin et al., 2008) 
PLGA based implant fabrication process was up scaled from laboratory methods to 
industrial manufacturing process by Wang et al., (2010). Haloperidol loaded PLGA 
implants were fabricated using two manufacturing techniques, solvent cast method and 
using single screw extrusion. Solvent casting method involves dissolution of polymer and 
drug mixture in acetone and then solvent is evaporated. Resulting film was compress 
molded into implants. In extrusion process, the mixture of powdered polymer and drug 
was extruded through a single screw extruder for fabrication of solid implants. The 
extrusion process was carried out over glass transition temperature of PLGA and below 
the melting point of haloperidol. The implants were characterized by surface morphology 
analysis and drug loading estimation. The PLGA implants loaded with haloperidol were 
evaluated by in vitro drug release and in vivo pharmacokinetic studies. In vitro release 
studies were performed in phosphate buffer saline (pH 7.4) stirred at 40 rpm and placed in 
dark at 37°C. In vivo studies were performed in rats after surgically inserting the 
haloperidol loaded PLGA based implant between dermis and muscle using a trocar. After 
placing implant the wound was closed. Blood samples were collected at pre determined 
time intervals and analyzed by a validated HPLC method. Scanning electron microscopy 
results revealed that implant were having both smooth and rough surface. The cross 
section observation with SEM shows porous nature of implants. In vitro release studies 
were characterized by a tri-phase release pattern. First phase of release was slower, 
followed by a rapid release phase and ended with a slow release phase. Haloperidol 
loaded PLGA implants release the drug for approximately 40 days, when studied for in 
vivo release. The in vivo release was higher at the end of first week and later followed by 
a steady state release. In vivo release results showed a consistent release pattern with in 
vitro release data. Authors suggested that solvent casting method was not feasible for 
large scale manufacturing process as it involves the use of organic solvents. They 
recommend the extrusion process may be optimized and up scaled for industrial purpose. 
In this study an optimized extrusion process for manufacturing of PLGA based implant 
with 40 % drug load of haloperidol was successfully developed. This study suggested that 
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further investigation may be done by using different molecular weight and ratio of lactide 
to glycolide in PLGA for further optimizing the formulations. (Wang et al., 2010)  
Siegel et al., (2001) developed a bioderagadable polymer based surgically implantable 
drug delivery system of haloperidol to increase the compliance in schizophrenic patients. 
Poly Lactic-co-Glycolic Acid (PLGA) of two different grades (75:25 PLGA and 85:15 
PLGA) was used in fabrication of implants. Implants were manufacture using a 
traditional solvent casting method in which polymer and drug were dissolved in acetone. 
Solvent was evaporated and resulted material was compressed by compression molding. 
Additionally a 100 % polylactide (PLA) was also employed as polymer for fabrication of 
implants. Implants were evaluated by in vitro release studies and behavioral testing in 
rats. In vitro release studies were performed in phosphate buffer saline placed on shaker at 
37° C. In vitro release data indicates a tri-phase release pattern. First phase of slow release 
is followed by more rapid release and ended with slow release. Haloperidol loaded 
implant fabricated with 75:25 PLGA and 85:15 PLGA released half of its drug load in 66 
and 86 days, respectively. Haloperidol loaded implants were surgically implanted in mice 
by producing a 1 cm surgical incision on dorsal aspect of animal and placing implant 
between dermis and muscle. In vivo studies were performed using locomotor activity and 
Western blots analysis. Locomotor activity results revealed that mice received haloperidol 
implant had significantly reduced motor activity than with control implant. Western blots 
assay also confirmed the presence of haloperidol at D2 receptors when compared with 
control. In conclusion the author advocated the use of long term surgically implantable 
devices based on PLGA for increasing the adherence in schizophrenic patients. (Siegel et al., 2001) 
(Desai et al., 2008) developed and evaluated PLGA based solid implant for sustained 
delivery of N-Acetylcysteine. N-Acetylcysteine is an anti cancer drug employed in the 
treatment of head and neck cancer. A long term treatment with N-Acetylcysteine (NAC) is 
required in cancer patients. Before the preparation of surgical implants, calcium and 
magnesium salts of NAC were prepared. PLGA based cylindrical implants of NAC were 
prepared using fluid energy micronization technique. Drug and polymer were dissolved in 
acetone and at 55% PLGA concentration, the solution is injected in silicone tubing. The 
silicone tubing was allowed to dry for two days at room temperature and three days in 
vacuum oven at 40°C. The silicone tubing was cut to obtain the cylindrical implant of 
NAC. Implant were characterized and evaluated with drug loading determination, x-ray 
diffraction studies, scanning electron microscopy and differential scanning cholorimetery. 
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In vitro release of NAC from PLGA implant was performed in phosphate buffer (pH 7.4) 
purged with nitrogen. NAC in dissolution medium was analyzed by using reverse phae 
chromatographic method with UV detection at 210 nm. Characterization parameters 
indicated a discrete suspension of NAC in PLGA implant. Initial burst release of NAC 
from PLGA implant was increased with increase in drug loading. Long term release rate 
was also increased with increase in initial drug loading. NAC causes the catalysis of 
PLGA polymer and study was aimed to prevent this catalysis. Due to this catalysis, the 
water uptake and degradation of polymer PLGA is enhanced. High water uptake and 
degradation of PLGA polymer leads to high initial burst release. Salts of NAC were 
successfully prepared and proved to prevent the catalysis of PLGA with NAC.   
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3. Materials and Methods 
This chapter includes the materials used in this study with their grade and supplier 
information. Methods portion covers the formulation parameters with preparation 
methods of PLGA based microspheres, in situ gelling system and PLGA based surgical 
implant. Methods employed in characterization, in vitro studies and in vivo studies are 
also described in this chapter.  
3.1 Materials  
Pure drug samples of Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H 
thieno[2,3][1,5]benzodiazepine) and Flouxetine were kindly gifted by Miracle 
Pharmaceuticals (Islamabad, Pakistan).  
Poly lactic-co-glycolic acid (PLGA)  biodegradable polymers of different ratio of lactic to 
glycolic acid (50:50 PLGA with Mw 75 kDa, 65:35 PLGA with Mw 82 kDa, 75:25 PLGA 
with Mw 90kDa and 85:15 PLGA with Mw 96 kDa) were obtained from Lakeshore 
biomaterials (USA).  
Polyvinyl alcohol (PVA; average mol. wt. =30,000 to 70,000) purchased from Sigma-
Aldrich (Steinheim, Germany). N-Isopropylacrylamide (NIPAM), N,N΄-
methylenebisacrylamide (MBA), Sodium dodecyl sulfate (SDS), Acrylic acid (AA),  
Potassium persulfate, Dulbecco’s modified Eagle’s medium (DMEM), Dimethyl 
sulfoxide (DMSO), Dimethylthiaol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
fetal bovine serum (FBS) were purchased from Sigma-Aldrich (Steinheim, Germany). N-
methyl-2-pyrrolidone (NMP) was also obtained from Sigma-Aldrich (Steinheim, 
Germany).  
HPLC grade Acetone, acetonitrile, methanol, dichloromethane (DCM) and ethanol were 
obtained from Merck (Germany) and used without further purification or filtration. All 
other chemicals were of analytical grade. 
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Table 3.1 Description of PLGA polymer grades used in formulations 
Polymers Form 
Composition 
(L:G) 
Inherent viscosity 
(dL/g) 
Mw 
(KDa) 
PDI 
 
PLGA 50:50 Granular 50:50 0.51 75 1.60 
PLGA 65:35 Granular 65:35 0.66 82 1.69 
PLGA 75:25 Pellets 75:25 0.74 90 1.70 
PLGA 85:15 Pellet 
85:15 
 
0.73 
 
96 
 
1.70 
 
L:G is lactide to glycolide ratio, Mw is molecular weight and PDI is Polydispersity Index 
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3.2 Methods 
3.2.1 HPLC method for determination of olanzapine in rat plasma 
3.2.1.2 Chromatographic instrumentation and conditions 
 Chromatographic studies were performed on Agilent separation module combined with 
solvent delivery pump model 1100 (USA). Chromatographic data was obtained by using 
computerized integration software HP ChemStation. A reverse phase chromatographic 
column C18 hypersil-BDS (250 mm-4.6 mm i.d, 5 µm) was used. Mobile phase consisted 
of 50% phosphate buffer of 50mM maintained at pH 5.5-Acetonitrile-methanol 
(50:30:20) (v/v/v) which was run at the flow rate of 1.2 mL/min. Mobile phase was 
filtered through 0.45 µm membrane by vacuum filtration and degassed by ultrasonicator 
prior to use. Detection of olanzapine was carried out on an ultraviolet detector at 214 nm. 
3.2.1.3 Sample preparation 
Quantification of olanzapine in micro-sample rat plasma was carried out using a modified 
HPLC method according to previously published HPLC method (Dusci et al., 2002). 
Olanzapine was extracted from the rat plasma samples by using liquid-liquid extraction. 
0.1 mL of plasma was taken in a 10 mL borosilicate glass tube, 10 µL of internal standard 
(I.S) solution (5 µg/mL of fluoxetine) was added to biological sample. 300 µL of 0.1 M 
Na2CO3 and 5 mL solution of hexane: dichloromethane (80:20) was added. The mixture 
was shaken for 5 minutes on a vortex mixer and then centrifuged at 2000 g for 5 minutes. 
Supernatant from this mixture was transferred to a 10 mL glass tube and evaporated under 
the stream of nitrogen. 100 µL of mobile phase was added and mixed on a vortex mixer. 
50 µL of this sample was injected to HPLC for analysis. 
3.2.1.4 Preparation of stock solutions 
Stock solutions of olanzapine and fluoxetine were prepared at concentration of 1 mg/mL 
in methanol. For preparation of working standard solutions, these stock solutions were 
further diluted with methanol. For olanzapine, its standard working solutions were 0.5, 1, 
5, 10, 50, 100, 200, 500 ng/mL. For Fluoxetine, its standard working solution was 500 
ng/mL. 
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3.2.1.5 Assay validation 
3.2.1.5.a Linearity 
Standard calibration curves were prepared by adding 10 µL of standard working dilutions 
of olanzapine and fluoxetine to 0.1 mL drug free rat plasma. Thus, corresponding plasma 
calibration standards of concentration 1, 5, 10, 50, 100, 200, 500 ng/mL of olanzapine and 
500 ng/mL of fluoxetine, were obtained. Plasma calibration standards were extracted by 
liquid-liquid extraction as method described above. Standard calibration curves were 
calculated by using peak area ratio of olanzapine and that of fluoxetine as function of 
olanzapine concentration in plasma. 
3.2.1.5.b Recovery 
Absolute recovery was calculated by comparing the peak areas of compounds after liquid-
liquid extraction with same concentration of compounds dissolved in mobile phase. For 
obtaining absolute recovery each measurement was taken in triplicate. 
Recovery (%) = 
                                             
                                  
      
3.2.1.5.c Intra-day and Inter-day variability 
Five different rat plasma samples were tested for intra-day variability by using a single 
calibration curve. Inter-day variability was tested on five days by using five different rat 
plasma samples. Standard calibration curve was constructed on each day for analysis. 
3.2.1.5.d Determination of LLOQ and LOD 
Lower limit of quantification (LLOQ) and lower limit of detection (LOD) for plasma 
samples of olanzapine was determined according to standards of FDA’s guidance for 
industry for bioanalytical method validation 2013 (F.D.A, 2001). LLOQ was determined 
by spiking the plasma with lowest concentration of calibration curve with 20% of 
precision and with 80-120% of accuracy by repeated analysis for five days. 
3.2.1.5.e Stability 
Freeze and thaw stability was determined by comparing freshly prepared QC samples 
with freeze thawed samples. Three concentrations (5, 100, 500 ng/mL) were used for five 
cycles of freeze thaw and analyzed in triplicates. Bench-top stability for 24 hours at room 
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temperature, stability of extracted samples for 24 hours at room temperature and long 
term stability for 100 days at -30°C was measured in three concentrations (5, 100, 500 
ng/mL) with six replicates.  
3.2.1.6 Pharmacokinetic application 
Above method was applied for pharmacokinetic evaluation of olanzapine in rats for 
preclinical studies. All experiments were performed in accordance with institutional 
guidelines for animal studies on Sprague–Dawley rats (260g ± 30). Rats were housed 
with free access to food and water. Oral single dose of olanzapine 7 mg/kg was given to 
overnight fasted rats (n=6) and blood samples (0.5 mL) were collected for each rat at 0.5, 
1, 3, 6, 12, 24 h from tail vein. Blood samples were centrifuged to separate the plasma 
which was stored in dark at - 30°C. All pharmacokinetic calculations were performed 
using software Thermo Kinetica 5.0 (Thermo Fisher Scientific, USA). 
3.2.2 Microsphere based depot parenteral formulation 
3.2.2.1 Preparation of olanzapine loaded microspheres 
PLGA microspheres loaded with olanzapine were prepared by using modified previously 
reported o/w solvent evaporation technique (Hickey et al., 2002). The organic phase was 
prepared by dissolving 50 mg olanzapine and 250 mg PLGA in the 10 mL mixture of 9:1 
dichloromethane and methanol (Table 3.2). This organic phase was transferred to 150 mL 
aqueous phase containing 1% PVA as an emulsifier. The resultant mixture was 
homogenized at different rates for 15 minutes at 8°C to obtain a sufficient emulsification. 
Then DCM was extracted at 37°C by stirring on a magnetic stirrer for 18 hours at 100 
rpm. The resultant solidified microspheres were obtained by filtration and washed thrice 
by deionized water. Microspheres were dried using a lyophilizer  (CHRIST ALPHA 1-4, 
Germany) and aqueous solution of mannitol was added during lyophilization to prevent 
the aggregation of microspheres. All formulations were sterilized using Gamma 
irradiation at 25 kGy using dry ice. Use of dry ice during gamma sterilization process 
significantly reduce the degradation of biodegradable polymers (Fernández-Carballido et 
al., 2006). 
3.2.2.2 Particle size analysis 
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Particle size of olanzapine loaded microspheres was determined using particle size 
analyzer based on laser diffraction technique (Malvern: Mastersizer 2000). Microspheres 
were suspended in small volume of distilled water and resultant suspension was added to 
50 mL continuously stirred distilled water and analyzed. Particle size of microspheres was 
determined as mean diameter in microns. Each sample was analyzed in triplicate and 
results were reported as mean values and standard deviation. 
 
Table 3.2 Formulation parameters of olanzapine loaded PLGA microspheres 
Formulation PLGA Polymer conc. 
(mg) 
Homogenization 
speed 
PVA 
(%) 
DCM:Methanol 
9:1 (mL) 
F1 50:50 200 2000 1 10 
F2 65:35 200 2000 1 10 
F3 75:25 200 2000 1 10 
F4 85:15 200 2000 1 10 
F5 75:25 250 2000 1 10 
F6 75:25 300 2000 1 10 
F7 75:25 250 2500 1 10 
F8 75:25 250 3000 1 10 
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3.2.2.3 Scanning electron microscopic analysis 
Surface morphology of microspheres was determined by scanning electron microscopic 
analysis (JEOL JSM 7500F). Small quantity of microspheres was loaded on carbon tape 
and coated with gold sputter of 20 nm. Samples were analyzed for surface morphology 
and shape using different magnification and following the standard procedure for 
analysis.  
3.2.2.4 Determination of encapsulated olanzapine in microspheres 
Encapsulation efficiency of olanzapine loaded microspheres was determined by 
dissolving 20 mg of microspheres in 3 mL of acetone. Resultant solution was further 
diluted by mobile phase and filtered (0.45 µm filter). Samples were analyzed using a 
reverse phase HPLC method. Reverse phase HPLC system consisted of Agilent 
separation module combined with solvent delivery pump model 1100 (USA). A reverse 
phase chromatographic column C18 hypersil-BDS (250 mm-4.6 mm i.d, 5 µm) was used. 
Mobile phase consisted of 50% phosphate buffer of 50mM maintained at pH 5.5- 
Acetonitrile-methanol (50:30:20) (v/v/v) which was run at the flow rate of 1.2 mL/min 
and detection of olanzapine was carried out on an ultraviolet detector at 260 nm. 
Encapsulation efficiency was determined using formula given below: 
Encapsulation efficiency (%) = [actual drug loading (%) / theoretical drug loading (%)] × 100 
Yield of microencapsulation process was determined by using formula given below: 
Percentage yield (%) = (practical yield / theoretical yield) × 100 
3.2.2.5 Measurement of bulk and tapped densities 
The loose bulk density (ρb) and the tapped density (ρt) of olanzapine microspheres were 
measured using a 10 mL cylinder. For tapped density the cylinder was tapped on the hard 
surface table for 20 taps. The two densities were calculated from the established equations 
1 and 2. 
ρb=(M)/(V0)                              (1) 
ρt=(M)/(Vf)                               (2) 
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Where ρb and ρt, bulk density and tapped density, respectively in g per mL; M, the 
weight of microspheres in g; V0, unsettled apparent volume in mL; Vf, the final tapped 
volume in mL. 
3.2.2.6 Fourier transform infrared spectrometry 
Fourier transform infrared spectrometry (FTIR) measurements were taken with Bruker 
Tensor 27 FT-IR system. Samples were directly loaded on Pike Miracle ATR cell and 
FTIR spectra were taken by first running a background spectrum. 
3.2.2.7 In vitro release analysis of olanzapine microcapsules 
In vitro release studies were performed by transferring 10 mg of PLGA microspheres 
loaded with olanzapine to 15 mL screw-cap centrifuge tube containing 6 mL of 50 mM 
phosphate buffer (pH 7.4). Tween 80 (0.02%) and sodium azide (0.05 %) was also added 
to above mixture and resultant mixture was incubated at 37°C on a shaker water bath 
running at 100 rpm. At predetermined time intervals, sample containing centrifuge tubes 
were centrifuged at 2000 rpm and 4 mL of supernatant was extracted and replaced with 
fresh buffer solution. Sample tubes were vortexed before placing in shaker water bath to 
prevent the aggregation of microspheres. Extracted supernatant was filtered through 0.45 
µm filter paper and analyzed for olanzapine concentration by same reverse phase HPLC 
method. In vitro release kinetics studies were performed using a Microsoft Excel based 
program DD solver (Zhang et al., 2010b). 
3.2.2.8 In vivo release studies of olanzapine microcapsules 
In vivo animal studies were conducted on male Sprague-Dawley rats divided into three 
groups (n=6) weighing approximately 280 g. Olanzapine loaded PLGA microspheres 
were suspended in normal saline immediately before injecting subcutaneously (20mg/kg 
olanzapine) into back of the neck of rat. Blood samples (0.5 mL) were collected from the 
tail vein on predetermined time intervals at 0, 0.125, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 
22, 24, 26, 28, 30, 32 and 36 days. Blood samples were centrifuged to separate the plasma 
which was stored in dark at - 30°C. The rats were provided with free access to food and 
water before and during the sampling. Plasma samples were analyzed by using a newly 
developed and validated HPLC method. Animal studies were approved by Pharmacy 
Research Ethics Committee, Department of Pharmacy, the Islamia University of 
Bahawalpur. Pharmacokinetic parameters for olanzapine PLGA microspheres in rat 
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plasma were calculated by using software Thermo Kinetica 5.0 (Thermo Fisher Scientific, 
USA). 
3.2.3 Depot parenteral formulations based on in situ gelling system 
3.2.3.1 PNA microgels based in situ gelling system 
3.2.3.1.a Preparation of olanzapine loaded PNA microgels 
Poly(N-isopropylacrylamide-co-acrylic acid) (PNA) microgels were prepared using a 
previously developed method, applying one of the optimized formulations (Xiong et al., 
2011). Initially, 2.6 g of NIPAM, 0.2 g of MBA and 0.116 g of SDS was added to 280 mL 
of water containing 10% AA. This solution was transferred to three necked flask fitted 
with reflux condenser. The solution was bubbled with nitrogen for at least 40 minutes to 
remove any oxygen from the solution. After purging with nitrogen the solution was 
heated on a magnetic stirrer at 300 rpm on 70°C. Potassium persulfate solution 
(0.14g/10mL) was rapidly added to above solution to initiate the process of 
polymerization. The polymerization process was carried out for 5 hours at 70°C. Residual 
monomers were removed by dialysis against water for 2 weeks. After dialysis, the 
microgels were separated and dried by using a freeze dryer. Formulation was sterilized 
with gamma irradiation at 25 kGy and degradation was prevented by using dry ice. 
Loading of olanzapine to microgels was done according to previously described 
procedure (Zhang et al., 2010a).  The freeze dried PNA microgels were immersed in 0.2 
mg/mL solution of olanzapine for 4 days. Drug loaded PNA microgel were washed with 
phosphate buffer saline (PBS) for three times and freeze dried or carried to dissolution 
medium for release studies. 
3.2.3.1.b Drug loading efficiency 
Drug loading efficiency of PNA microgels was calculated using following formula: 
Wdrug / Wdried microgel × 100 % 
Where Wdrug is weight of drug in dosage form and Wdried microgel is weight of drug loaded 
freeze dried PNA microgel.  
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3.2.3.1.c Transmission electron microscopic analysis 
Transmission electron microscope (TEM) was used to analyze the morphology of 
olanzapine loaded PNA microgels. A dispersion of microgels was deposited on a carbon 
coated formvar grid. These grids were air dried and observed with TEM (JEOL JEM-
1010) at accelerating voltage of 100 kV.  
3.2.3.1.d Measurement of viscosities 
Viscosity of olanzapine loaded PNA microgels was evaluated at various pH and 
temperature range. Viscosity at different pH values was determined by dispersing the 
microgels (8%) in citric acid-phosphate buffer solution of pH values 5.0 and 7.4. 
Viscosity at various temperatures was measured by using dispersion of microgels (8%) 
and temperature was varied using thermostat at range of 20-45°C. All viscosity 
measurements were taken on programmable viscometer (Brookfield DV-II pro, USA). 
3.2.3.1.e Measurement of cytotoxicity with MTT assay 
Dimethylthiaol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method was used to 
evaluate the cytotoxicity of olanzapine loaded PNA microgels. Briefly NH 3T3 (Mouse 
embryonic fibroblast cells) cells were seeded at 5000 cells per µL in each well of 96-well 
plate. Well plate was maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 
100 U/mL of penicillin, 100 µg/mL streptomycin and 10% heat inactivated Fetal bovine 
serum (FBS). Well plate was incubated for 1 day in 5% CO2 atmosphere at 37°C and 100 
µL of olanzapine loaded microgel dispersion was added to culture medium. After adding 
microgels, this culture medium was incubated for various time periods. After incubation 
time point the culture medium was replaced with MTT solution (5 mg/mL) and incubated 
for 4 hours in dark at 37°C. Then MTT solution was replaced with Dimethyl sulfoxide 
(DMSO) (200 µL) and stirred at room temperature. Samples were analyzed with optical 
rotation measured at 490 nm.  
3.2.3.1.f In vitro release studies 
In vitro release of olanzapine from PNA microgels was determined on different pH and 
temperature range. PNA microgels were placed in phosphate buffer saline (PBS) with pH 
7.4 and at 37°C. At predetermined time intervals the samples were collected and replaced 
with fresh PBS. The samples were analyzed for olanzapine concentration using ultraviolet 
spectrophotometer (Shimadzu, Japan) at 226 nm. 
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3.2.3.1.g In vivo studies of Olanzapine loaded PNA microgels 
In vivo studies were performed on male Sprague-Dawley rats with average weight of 
315±23 grams. Rats were divided into two groups (n=6) and provided with free access to 
food and water at all the time during study. Control group of animals was administered 
with oral dose of olanzapine (7 mg/kg) and test group was administered with 
subcutaneous injection of olanzapine (7 mg/kg) loaded PNA microgels suspended in 
normal saline. All animals were observed for 72 hours prior to study for any abnormality. 
Animal studies were approved by Pharmacy Research Ethics Committee, Department of 
Pharmacy, the Islamia University of Bahawalpur and all experiments were performed in 
accordance with international guidelines for animal (N.I.H, 1985). Blood samples (0.5 
mL) from tail vein were collected at 0, 1, 3, 6, 12, 24, 36, 48, 60 and 72 hours. All blood 
samples were immediately centrifuged at 4500 g for 10 minutes and plasma was 
separated and stored at -80°C in dark. Plasma samples were brought to room temperature 
before analyzing with a previously developed and validated reverse phase HPLC method. 
Thermo Kinetica 5.0 (Thermo Fisher Scientific, USA) was used to evaluate the 
pharmacokinetic parameters of olanzapine in rat plasma.  
3.2.3.1.h Statistical Analysis 
Results were statistically investigated for significant difference by using t-test at 5% 
significance level and considered significantly different if value of p ≤ 0.05. All statistical 
analysis was performed using Microsoft excel-2010 software package. 
3.2.3.2 Phase sensitive PLGA based in situ gelling system 
3.2.3.2.a Preparation of in situ gelling implant 
Solutions with different concentrations of polymer in NMP were prepared using different 
grades of PLGA as shown in Table 3.3. To make polymer solution, PLGA was dissolved 
in NMP by adding weighed amount of PLGA to NMP in a vial and placed it for 24 hours 
on a thermo-shaker (Hangzhou AllSheng China) at 37°C. Olanzapine (5% w/v) was 
added to resultant solution by homogenization at 7000 rpm for 3 minutes for the drug to 
be dissolved completely. Formulations were sterilized by using gamma radiation at 25 
kGy and degradation was prevented by using dry ice. All formulations were stored in 
refrigerator at 8°C. 
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Table 3.3 Formulation parameters of PLGA based in situ implant gel for olanzapine  
Formulation PLGA 
Conc. of PLGA in NMP 
w/v (%) 
Drug Loading w/v 
(%) 
F1 50:50 40 5 
F2 65:35 40 5 
F3 75:25 40 5 
F4 85:15 40 5 
F5 75:25 30 5 
F6 75:25 20 5 
 
 
3.2.3.2.b In vitro release of olanzapine 
In vitro release studies were performed by transferring a measured amount of formulation 
solution to 21-guage disposable syringe. The solution was injected to 20 mL phosphate 
buffer (pH 7.4) and incubated at 37°C. Sodium azide (0.01%) was added to above media 
to avoid microbial contamination. At predetermined time intervals, a 2 mL sample was 
withdrawn and replaced with fresh phosphate buffer containing sodium azide. The 
samples were evaluated for olanzapine concentration by using a validated reverse phase 
HPLC method. Separation was performed on Agilent separation module combined with 
solvent delivery pump model 1100 (USA). A reverse phase C18 hypersil-BDS (250 mm-
4.6 mm i.d, 5 µm) column was used. Mobile phase consisted of 50% phosphate buffer of 
50mM maintained at pH 5.5- Acetonitrile-methanol (50:30:20) (v/v/v) which was run at 
the flow rate of 1.2 mL/min and detection of olanzapine was carried out on an ultraviolet 
detector at 260 nm. 
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3.2.3.2.c Scanning electron microscopic studies 
Scanning electron microscope (JEOL JSM 7500F) was used to determine the morphology 
of in situ gel. Formulation solution was injected to 20 mL phosphate buffer (pH 7.4) and 
placed in incubator at 37°C for 24 hours. Resultant gel was collected and dried by using 
freeze dryer (CHRIST ALPHA 1-4, Germany). Longitudinal cross sections of gel were 
obtained and coated with sputter of gold and observed by electron microscope for their 
morphology. 
3.2.3.2.d Fourier transform infrared spectrometric analysis 
Fourier transform infrared spectrometry (FTIR) spectra of pure drug, PLGA solution and 
formulations were obtained with Bruker Tensor 27 FT-IR system. Samples were 
transferred to a Pike Miracle ATR cell and analyzed. FTIR spectra were obtained by first 
running a background scan for each sample.   
3.2.3.2.e Viscosity measurement of formulation solutions 
Viscosity of formulation solutions was measure using a cone plate programmable 
viscometer (Brookfield HADV-II, USA). Viscosity measurements were taken at 25°C 
(water bath with digital controlled thermostat) and with shear rate of 100 s
-1
. All samples 
were analyzed for viscosity in triplicate and average was taken. 
3.2.3.2.f In vivo studies of Olanzapine in situ gelling implant 
In vivo studies were performed on male Sprague-Dawley rats with average weight of 300 
grams. Animals were divided in to three groups of six animals each and were observed for 
7 days before study with free access to food and water at all time. This study was 
approved for animal studies by Pharmacy Research Ethics Committee, Department of 
Pharmacy, the Islamia University of Bahawalpur. All formulations were brought to room 
temperature before injecting the formulation solution (0.15 mL) as a bolus injection into 
subcutaneous tissue of dorsolateral region of neck of rat. All animals were provided with 
free access to food and water throughout the study. Blood samples (0.5 mL) from tail vein 
were collected at 0, 0.125, 1, 2, 3, 5, 7, 10, 13, 17, 20, 24, 28, 32 and 36 days. All blood 
samples were immediately centrifuged at 4500 g for 10 min and plasma was separated 
and stored at -80°C in dark. Plasma samples were brought to room temperature before 
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analyzing with a previously developed and validated reverse phase HPLC method. 
Thermo Kinetica 5.0 (Thermo Fisher Scientific, USA) was used to evaluate the 
pharmacokinetic parameters for olanzapine in rat plasma.  
3.2.4 Depot parenteral formulations based solid PLGA implant 
3.2.4.1 Fabrication of Olanzapine Implant  
Development of olanzapine loaded PLGA implant was based on the principle of fluid 
energy micronization (FEM) and solvent extrusion (Zhang et al., 1993). A modified FEM 
and solvent extrusion method was used to fabricate the surgically implantable olanzapine 
cylinders (Zhou et al., 1998). Briefly, olanzapine was dissolved in excess of the acetone 
and PLGA was added to above solution. Resultant mixture was kept on a shaker at 37°C 
until the PLGA is completely dissolved. Excess of acetone was evaporated to make 
polymer concentration to 60% w/w with respect to solvent. The concentrated solution was 
loaded in a 3 mL syringe and injected at the rate 0.1 mL per minute into a silicone tube 
(internal diameter = 1 mm). Silicone tube was detached and dried at room temperature for 
48 hours and further dried in oven at 40°C for 72 hours. After drying, the silicon tube was 
carefully cut by using a heated knife and solid cylindrical implants were separated. 
Various batches of implants were produced by changing lactide to glycolide ratio in 
PLGA and drug loading (w/w to polymer) as shown in Table 3.3. Olanzapine loaded 
implant formulations were sterilized using Gamma irradiation at 25 kGy. Dry ice was 
used during sterilization process to prevent the degradation of PLGA (Fernández-
Carballido et al., 2006). 
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Table 3.4  Formulation parameters of PLGA implant for olanzapine  
Formulation PLGA Olanzapine w/w (%) 
F1 50:50 40 
F2 65:35 40 
F3 75:25 40 
F4 85:15 40 
F5 75:25 30 
F6 75:25 20 
 
3.2.4.2 Evaluation of drug loading 
Formulated cylindrical rods were appropriately weighed and cut for evaluation. These 
weighed sample cylinders were transferred to flask containing 10 mL of acetonitrile and 
dissolved by placing on vortex mixer for 10 minutes. A sample of 100 µL was taken from 
the resultant solution and transferred to another flask containing 10 mL phosphate buffer 
solution (pH 7.4) and again vortexed for 10 minutes. Samples were quantified for 
olanzapine by using ultraviolet spectrophotometer (Shimadzu, Japan) at 226 nm. 
3.2.4.3 In vitro release studies 
In vitro release studies were performed according to USP guidelines for simulating the 
conditions for subcutaneous environment (Wang et al., 2010). Three replicates of each 
formulation batch were placed in amber colored jar containing 500 mL of phosphate 
buffer saline (pH 7.4). The jars were screw capped and placed at 37°C on a shaker 
platform at 40 rpm. Sodium azide (0.01 %) was added to dissolution medium to prevent 
the microbial growth. On alternate days, a 1 mL sample was withdrawn from each 
container and replaced with fresh phosphate buffer saline. Samples were analyzed using a 
validated RP-HPLC method with ultraviolet detection. Effect of changing lactide to 
glycolide ratio in PLGA and changing drug loading on release profiles was evaluated.  
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3.2.4.4 Scanning electron microscopic analysis 
Surface morphology of implants was evaluated using scanning electron microscopic 
(SEM) analysis (JEOL JSM 7500F). Surfaces of freshly prepared implant and implant 
removed from dissolution medium after immersion for 7 days were coated with gold 
sputter of 20 nm. Samples were loaded on a carbon tape and analyzed at different 
magnifications using standard operating procedures.  
3.2.4.5 X-ray diffractometric analysis 
Samples of olanzapine, PLGA and implant formulations were studied using X-ray 
diffraction (XRD) for their crystallinity. X-ray diffractometer (Bruker D8 Discover, 
Germany) was set over the range of 8º to 60° diffraction angle (2θ) and at the rate of 5º 
per minute to measure crystallinity.  Diffractometer was on tube voltage of 35 kV and 
having current of 35 mA. 
3.2.4.6 Fourier transform infrared spectrometry 
Fourier transform infrared spectrometry (FTIR) measurements were taken with Bruker 
Tensor 27 FT-IR system. Samples of pure drug, polymer PLGA and implants were loaded 
on Pike Miracle ATR cell to analyze with FTIR spectra after running a background 
spectrum scan. 
3.2.4.7 Differential scanning calorimetric analysis 
Differential scanning calorimetric (DSC) analysis of PLGA polymer, olanzapine and 
implant were performed on MTDSC model 2910 (TA Instruments, New Castle, USA). 
Samples of 5 mg loaded on aluminum pans sealed with lids. All samples were analyzed 
by heating from 20°C to 200°C with incremental rate of 10°C per minute. Dry nitrogen 
flow was maintained in MTDSC cell at 40 mL per minute. 
3.2.4.8 In vivo release and pharmacokinetic analysis 
In vivo studies were performed on Sprague-Dawley rats weighing approximately 300 g 
each. The animals were divided into three groups of six animals each and observed for 
three days prior to study by providing free access to food and water. Animal studies were 
approved by Pharmacy Research Ethics Committee, Department of Pharmacy, the Islamia 
 
42 
 
University of Bahawalpur. All animals were housed and handled according to institutional 
guidelines prior and during study.  
Prior to implantation surgery, the rats were anesthetized using intra-peritoneal injection of 
xylazine (10 mg/kg) and ketamine (100 mg/kg). Dorsal aspect of the animal was shaved 
and cleaned for surgical implantation. A scalpel incision of 1 cm was made on dorsal 
region and a pocket between dermis and muscle was made and visualized with the help of 
hemostatic clamp. Implant formulation was placed in this pocket between dermis and 
muscle with the help of forceps. Implantation wound was closed with a single surgical 
stitch. 
Blood samples of 0.5 mL from the tail vein of rats were collected on 0, 1, 3, 5, 7, 10, 13, 
16, 20, 25, 30, 35, 40, 45, 50, 60, 70 and 80 days. Plasma samples were obtained by 
centrifuging the blood samples at 4500 rpm for 10 minutes. Plasma samples were stored 
in dark at -80°C prior to analysis. Olanzapine concentration in plasma sample was 
determined using a validated RP-HPLC method with ultraviolet detection. Plasma 
concentration versus time curves were plotted and pharmacokinetic parameters were 
evaluated using software Thermo Kinetica 5.0 (Thermo Fisher Scientific, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
4.1 HPLC Method for Determination of Olanzapine in Rat Plasma 
4.1.1 Chromatographic separation 
Different ratios of buffer, acetonitrile and methanol were used to obtain the best 
chromatographic conditions. Type of column and pH of buffer was also optimized to get 
the better sensitivity and selectivity of analysis. Chromatograms of blank plasma and drug 
free plasma spiked with 100 ng of olanzapine and 500 ng of fluoxetine (I.S) is illustrated 
in (Figure 4.1). Retention times of olanzapine and internal standard (fluoxetine) were 5.0 
minutes and 13.4 minutes, respectively. 
4.1.2 Method validation 
4.1.2.1 Linearity and limit of quantification 
Standard curve was established by taking ratio of peak area of olanzapine and that of 
fluoxetine (I.S) as a function of olanzapine plasma concentration. Excellent linearity with 
concentration range 1-500 ng/mL in rat plasma was obtained with coefficient of 
regression i.e. r
2
 =0.9986. Lowest limit of quantification (LLOQ) in rat plasma with 
acceptable precision and accuracy (n=5, R.S.D.: 12.4%, Deviation: -3%) was 1 ng/mL. 
Limit of detection was 0.5 ng/mL with minimum signal to noise ratio of three.   
4.1.2.2 Precision and Accuracy 
Inter-day and intra-day accuracy and precision values for 1, 5, 10, 50, 100, 200, 500 
ng/mL plasma concentration are shown in (Table 4.1). Five replicates were used to 
determine the Inter-day and intra-day precision by calculating RSD%. Inter-day and intra-
day precision was found to be lower than 12.5% and 5.1% respectively whereas accuracy 
of this method was in between 94% and 105%. These results show that precision and 
accuracy of analytical method developed for determining olanzapine in plasma is within 
the limits established by FDA for bioanalytical method (F.D.A, 2001).
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Figure 4.1 Chromatogram of rat plasma extract using UV detection at 214 nm. 2(a) 
blank plasma; 2(b) plasma spiked with A= Olanzapine 100 ng/mL and B= 
fluoxetine 500 ng/mL; 2(c) plasma sample taken from rat treated with 7 
mg/kg after 1 hour and spiked with internal standard fluoxetine 500 ng/mL  
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4.1.2.3 Extraction recovery 
A convenient single step liquid-liquid extraction method was employed which provided a 
comparable recovery to other methods employing solid phase extraction (SPE). 
Extraction recovery of olanzapine was measured at 1, 50, 500 ng/mL and 500 ng/mL for 
fluoxetine (I.S) using triplicate samples. Results showed that extraction recovery was 
greater than 82% for all observed concentration in rat plasma which is comparable with 
SPE method (Raggi et al., 2000; Chiu and Franklin, 1996). Extraction recoveries of 
Olanzapine and internal standard are shown in (Table 4.2). Ascorbic acid was not added 
to the plasma samples as addition of ascorbic acid does not affect the stability of 
olanzapine during storage and extraction (Dusci et al., 2002). 
4.1.2.4 Stability 
Changes in stability for plasma samples stored at -30°C after  5 freeze thawing cycles is 
shown in (Table 4.3). Bench-top stability and extracted sample stability were measured at 
room temperature and long term stability was measured at -30° C as shown in (Table 4.4). 
All the stability parameters were found to meet the acceptance criteria of FDA’s guidance 
for industry for bioanalytical method validation 2013 (F.D.A, 2001).
 
Long term stability 
for olanzapine in plasma sample at -30°C was for a minimum of 100 days.  
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Table 4.1 Inter-day and Intra-day precision and accuracy of HPLC method for 
olanzapine in rat plasma  
Concentration spiked 
(ng/mL) 
Mean concentration 
calculated 
(ng/mL) 
S.D RSD 
(%)
a 
Accuracy 
(%)
 
Inter-day (n=5) 
1 1.05 0.13 12.4 105 
5 4.92 0.08 1.7 98.4 
50 47 3.46 7.4 94 
100 97.70 4.68 4.8 97.7 
200 201.1 0.85 0.4 100.6 
500 484.4 28.94 6.0 96.9 
Intra-day (n=5) 
1 0.96 0.02 1.6 95.7 
5 5.04 0.25 5.0 100.8 
50 47.97 0.71 1.5 95.9 
100 100.87 2.46 2.4 100.9 
200 197.23 2.95 1.5 98.6 
500 485.67 5.03 1.0 97.1 
a 
RSD values of normalized areas are the averages from three concentration levels of the calibration curves. 
 
 
 
 
 
 
 
47 
 
Table 4.2 Percentage extraction recoveries of olanzapine and fluoxetine from rat 
plasma 
Concentration spiked 
ng/mL 
Peak area 
(mean ± S.D, n=3) Recovery 
(%)
b 
Extracted Unextracted 
Olanzapine 
1 2.4 ± 0.1 2.8 ± 0.1 83 
50 114.0 ± 1.4 133.2 ± 1.3 86 
500 1177.4 ± 31.0 1275.2 ± 11.0 92 
Fluoxetine (I.S) 
500 446.2 ± 2.9 508.2 ± 3.0 88 
b 
Recovery mean values obtained from three individual samples on three different days at three 
concentration levels. 
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Table 4.3 Freeze thaw stability of plasma samples after 5 cycles (n=3) 
Cycle 
Concentration 
(ng/mL) 
Mean Stability 
sample 
(ng/mL) 
CV (%)
a 
Change (%)
b
 
1 
5 4.93 2.1 -1.4 
100 98.4 3.5 -1.6 
500 495.1 2.8 -0.98 
2 
5 4.91 6.1 -1.8 
100 98.5 5.4 -1.5 
500 492.3 3.8 -1.54 
3 
5 4.88 1.9 -2.4 
100 91.9 6.5 -8.1 
500 491.2 3.9 -1.76 
4 
5 4.81 2.4 -3.8 
100 90.7 1.5 -9.3 
500 486.4 4.1 -2.72 
5 
5 4.7 1.9 -6 
100 90.3 3.4 -9.7 
500 485.1 2.9 -2.98 
a
 CV: coefficient of variation 
b             
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Table 4.4 Stability parameters of olanzapine plasma samples at different storage 
conditions (n=6) 
Stability 
Parameter 
Storage 
Condition 
Concentration 
(ng/mL) 
Mean stability 
sample (ng/mL) 
CV (%)
a
 Change 
(%)
b
 
Bench top 
stability 
Room 
temperature 
for 24 h 
5 4.87 1.3 -2.6 
100 98 3.2 -2 
500 493.5 0.9 -1.3 
Long term 
stability 
At -30° C 
for 100 days 
 
5 4.81 5.3 -3.8 
100 90.7 2.8 -9.3 
500 485.6 3.7 -2.88 
Extracted 
sample 
stability 
Room 
temperature 
for 48 h 
5 4.95 0.5 -1.0 
100 98.8 1.8 -1.2 
500 498.9 2.8 -0.22 
a
 CV: coefficient of variation 
b             
                                        
                   
      
 
4.1.3 Application of validated method for pharmacokinetic studies 
Application of validated HPLC method was demonstrated in the pharmacokinetic 
evaluation of olanzapine in rats for preclinical studies. Plasma concentration was 
determined over period of 24 hours after single oral administration of olanzapine 7 mg/kg 
and assay was proved to be sensitive enough to measure plasma concentration over 24 
hours. Plasma concentration versus time curves after 7 mg/kg oral administration of 
olanzapine is shown in (Figure 4.2). Non-compartmental pharmacokinetic parameter were 
calculated by Kinetica 5.0 software (Thermo Fisher Scientific, USA), which are described 
in (Table 4.5). The mean Cmax of olanzapine was 412.7 ng/mL, tmax was 1 hour and half 
life t1/2 was 2.54 hours, which were found in accordance with the pharmacokinetic 
parameters observed in other studies (Raggi et al., 2000; Chiu and Franklin, 1996). 
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Figure 4.2 Mean concentration-time curves after oral administration of 7 mg/kg of 
olanzapine in rats 
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Table 4.5 Non-compartmental pharmacokinetic parameters of olanzapine Mean ± 
S.D in rats (n=6) after oral dose of 7 mg/kg 
Parameter Unit Mean ± S.D 
t1/2 h 2.54 0.25 
Tmax h 1 0.00 
Cmax ng/mL 412.7 18.7 
AUC 0-t (ng.h/mL) 1956.7 119.2 
AUC 0-inf (ng.h/mL) 1959.5 119.5 
MRT 0-inf h 4.6 0.29 
Where t1/2 is half life, Tmax is time for maximum concentration, Cmax is maximum plasma concentration, 
AUC is area under plasma vs time curve, MRT is maximum residence time, h=hours and S.D is standard 
deviation.  
 
4.2 Microsphere based depot parenteral formulation 
In present research biodegradable polymer (PLGA) based microcapsules were developed 
to increase the compliance of olanzapine use in schizophrenia. Solvent evaporation 
method was used to fabricate the microspheres which were targeted to release the drug for 
30 days. Solvent evaporation method using single (o/w) emulsion was used due to its ease 
of production and scale-up of process. Previously PLGA microspheres were also 
produced using more complicated methods like double emulsion, pressing and casting 
(Hickey et al., 2002). Different PLGA polymers having variable ratio of lactic to glycolic 
acid were used and some other formulation parameters were also optimized to get a set of 
formulation batches. 
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4.2.1 Particle size, surface morphology and bulk density analysis 
Olanzapine microspheres produced by solvent evaporation method were having spherical 
shape and smooth surface with very few pores. Polymer precipitation and solvent removal 
from the emulsion system are main factors that govern the morphology of microspheres 
(Khang et al., 2000). Smooth surface of microspheres results when solvent evaporates 
slowly which gives a gradual and slow precipitation of polymer. PVA concentration of 
water phase in o/w emulsion is also responsible for smooth surface morphology and 
stability of microspheres (Choi et al., 2002). Surface morphology and shape of 
microspheres is shown in SEM images (Figure 4.3).  
Size of the microspheres is dependent on many factors including polymer type, polymer 
concentration in organic phase, homogenization speed, temperature during preparation, 
stirring rate at the hardening step and amount of surfactant added during hardening phase 
(Yan Wang and Burgess, 2012). Size of olanzapine loaded microspheres range from 9.71 
µm to 19.90 µm in mean diameter as shown in Table 4.6. Results shows that 
microspheres size is increased as the lactic to glycolic acid ratio, molecular weight of 
polymer and concentration of polymer in organic phase is increased and vice versa. 
Increase in homogenization speed during emulsification decrease the mean diameter of 
microspheres. Size of olanzapine microspheres prepared in this study is less than 
olanzapine loaded PLGA microspheres produced in previous studies (D’souza et al., 
2013; Nahata and Saini, 2008). Desirable size of microspheres was obtained to get ease of 
administration and desired release rates. Small particle size of microspheres in aqueous 
microsphere suspension for subcutaneous injection increases the ease of syringeability 
and administration (Cheng et al., 1998). Size of microspheres was not decreased to a level 
(2-6 µm) where phagocytosis of microspheres would cause a problem (Champion et al., 
2008).  
Bulk density and tapped densities of microspheres were in the range of 0.71 to 0.78 and 
0.76 to 0.82, respectively as shown in Table 4.7. Less difference between bulk and tapped 
densities shows the uniformity of microsphere shape and better flowability (Yüce and 
Canefe, 2008).  
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4.2.2 Formulation parameters and encapsulation efficiency 
Encapsulation efficiency is influenced by chemical properties of encapsulation polymer, 
solvents, preparation temperature and drug polymer interactions. Encapsulation efficiency 
of olanzapine loaded microspheres was in the range of 78.53% to 96.12% as shown in 
Table 4.8. Encapsulation efficiency was affected by changing the ratio of lactic to glycolic 
acid in copolymer PLGA and result shows that as ratio is increased the encapsulation 
efficiency was also increased. Higher concentration of encapsulating polymer also has an 
incremental effect on encapsulation efficiency.  A previous study also showed that 
increase in molecular weight and concentration of polymer increased the encapsulation 
efficiency (Su et al., 2009). Encapsulation efficiency was decreased as size of 
microsphere was reduced because smaller microcapsules have low drug encapsulation 
due to higher surface/solvent ratio causing drug to diffuse out (Su et al., 2009). In Present 
Study low preparation temperature (8°C) was also responsible for higher encapsulation 
efficiencies as in a previous study it was shown that at lower preparation temperatures, 
the encapsulation efficiency of PLGA is enhanced (Nahata and Saini, 2008).  
 
Table 4.6 Size distribution of olanzapine loaded PLGA microspheres with different 
formulation parameters 
Formulati
on 
PLGA Polymer 
conc. (mg) 
Homogenization 
speed 
Size ± S.D 
(µm) 
F1 50:50 200 2000 10.51 ± 0.13 
F2 65:35 200 2000 10.82 ± 0.13 
F3 75:25 200 2000 12.20 ± 0.20 
F4 85:15 200 2000 14.81 ± 0.24 
F5 75:25 250 2000 14.31 ± 0.12 
F6 75:25 300 2000 19.92 ± 0.09 
F7 75:25 250 2500 12.23 ± 0.14 
F8 75:25 250 3000 9.71 ± 0.08 
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Figure 4.3 SEM images of olanzapine loaded microsphere formulations: 1(A) of 
formulation F8, 1(B) of Formulation F1 and 1(C) of formulation F6 
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Table 4.7 Bulk and tapped densities of different formulations of olanzapine loaded 
PLGA microspheres 
Formulation PLGA Polymer 
(mg) 
Homogenization 
speed (rpm) 
Bulk 
Density 
Tapped 
Density 
F1 50:50 200 2000 0.75 0.79 
F2 65:35 200 2000 0.77 0.80 
F3 75:25 200 2000 0.76 0.80 
F4 85:15 200 2000 0.78 0.82 
F5 75:25 250 2000 0.73 0.78 
F6 75:25 300 2000 0.74 0.79 
F7 75:25 250 2500 0.75 0.78 
F8 75:25 250 3000 0.71 0.76 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Table 4.8 Encapsulation efficiency and yield of different formulations of olanzapine 
loaded PLGA microspheres 
Formulation PLGA 
Polymer 
(mg) 
Homogenization 
speed (rpm) 
Encapsulation 
efficiency 
Yield 
F1 50:50 200 2000 85.94 % 81.54 % 
F2 65:35 200 2000 89.91% 80.14 % 
F3 75:25 200 2000 90.84 % 82.51 % 
F4 85:15 200 2000 96.12 % 82.24 % 
F5 75:25 250 2000 91.32 % 79.91 % 
F6 75:25 300 2000 92.14 % 78.56 % 
F7 75:25 250 2500 82.14 % 84.11 % 
F8 75:25 250 3000 78.53 % 79.31 % 
 
4.2.3 FTIR studies of microspheres 
In FTIR spectra of PLGA the characteristic peaks were observed for C-O stretching 
(1050-1270 cm
-1
), carbonyl-C=O stretching (1700-1800 cm
-1
) and –CH, -CH2, -CH3 
stretching vibrations (2900-3000 cm
-1
). Characteristic peaks of olanzapine were observed 
for NH, OH stretching (3220.94 cm
-1
), C-H stretching (2934.05 cm
-1
), C=C stretching 
(1582.94 cm
-1
), C=N stretching (1410.66 cm
-1
) and C-S stretching (744.77 cm
-1
). FTIR 
spectra olanzapine loaded microspheres showed the combination of PLGA and olanzapine 
peaks in which some peaks of olanzapine were overlapped by PLGA peaks as shown in 
Figure 4.4. FTIR studies indicate that there is little or no interaction between olanzapine 
and PLGA in microspheres. 
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Figure 4.4 FTIR spectra of (A) PLGA 75:25, (B) of olanzapine and (C) of Olanzapine 
loaded microspheres 
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4.2.4 In vitro release of olanzapine from PLGA microspheres 
Present research has shown that in vitro release of olanzapine is significantly affected by 
the formulation parameters and process variable as shown in Figure 4.5, Figure 4.6 & 
Figure 4.7 and tabulated in Table 4.9, Table 4.10 & Table 4.11. A previous study indicates 
that release of drug from PLGA microspheres is dependent on polymer type and 
molecular weight, process variables, properties of drug and particle size of microcapsules 
(Tracy et al., 1999). In vitro release studies with changing the ratio of lactic to glycolic 
acid (50:50, 65:35, 75:25, 85:15)  in copolymer PLGA was done and it was observed that 
as ratio was increased the release of drug was decreased as shown in Figure 4.5. Release 
of olanzapine from PLGA 50:50 microspheres was fastest whereas release from PLGA 
85:15 microspheres was slowest of all. This effect was also resulted from the difference in 
molecular weights of the polymers, release of olanzapine from microspheres decrease 
with the increase in molecular weight of polymer. Decrease in molecular weight of PLGA 
polymer increases the diffusion of drug, erosion of polymer and water permeation of 
PLGA microspheres (Fu et al., 2005). 
In vitro release of olanzapine was significantly affected by change in size of PLGA 
microcapsules.  Three formulations namely F5, F7 and F8 were prepared with same 
PLGA (75:25) polymer but by changing the homogenization speed, their size were 
different. F8 with least particle size showed the fastest release and F5 with largest particle 
size showed a slowest release as shown in Figure 4.6. Reducing the size of microspheres 
increases the surface/volume ratio, which increase the diffusion of drug form 
microspheres (Su et al., 2009). Effect of increasing the polymer ratio in organic phase 
was evaluated for in vitro release as shown in Figure 4.7. Release studies show that 
increasing the polymer concentration in organic phase decrease the release rate of 
olanzapine from microspheres. The effect was observed because as the polymer ratio in 
organic phase is increased the thickness of polymer wall and size of microsphere was 
increased resulting in slower rate.  
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Table 4.9 In vitro percentage cumulative release profiles of different formulations of 
olanzapine microspheres with different grades of PLGA 
Time 
Formulations 
F1 (PLGA 50:50) F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
0 0 0 0 0 0 0 0 0 
1 4.12 0.51 1.85 0.12 2.2 0.2 5.78 0.5 
2 7.98 0.62 7.85 0.81 4.12 0.5 8.58 0.22 
3 15.23 0.88 13.5 2.4 7.1 1.1 9.89 0.42 
4 23.79 1.2 19.2 2.54 12.14 1.4 12.51 0.52 
6 30.51 1.8 26.13 2.1 15.99 1.2 14.11 1.8 
8 38.21 1.91 32.99 2.54 19.3 1.6 16.23 1.7 
10 45.93 2.2 36.25 2.95 24.12 1.7 20.41 2.1 
12 52.12 2.45 40.17 3.12 30.01 2.4 21.12 2.5 
14 56.34 2.31 45.21 3.25 34.8 2.7 26.01 2.7 
16 62.14 2.74 51.96 3.11 39.1 3.1 30.2 3.1 
18 65.89 2.54 60.21 3.85 43.94 3 33.15 3.2 
20 73.21 2.91 68.35 3.94 48.79 3.4 39.21 3.8 
22 78.12 3.51 73.11 3.86 53.81 3.8 43 4.1 
24 83.21 3.12 77.51 4.12 58.02 4.1 45.12 4.5 
26 92.31 3.56 81.94 4.02 62.13 4.5 51.89 4.7 
28 97.24 3.87 85.12 3.94 68.76 4.3 54.11 4.9 
30 99.81 3.98 91.11 4.26 75.14 5.1 58.21 4.51 
32 99.81 4.01 99.01 4.85 81.2 5.2 62.17 4.23 
34 99.81 3.75 99.01 5.01 90.1 4.9 66.86 4.71 
36 100 4.11 99.01 4.87 93.51 4.8 75.42 4.18 
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Table 4.10 In vitro percentage cumulative release profiles of different formulations of 
olanzapine PLGA microspheres with different size distribution 
Time 
Formulations 
F5 (14.31 µm) F7 (12.23 µm) F8 (9.71 µm) 
Days Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D 
0 0 0 0 0 0 0 
1 2 0.2 2 0.16 2.41 0.13 
2 3.61 0.8 4.21 0.19 4.39 0.51 
3 6.12 1.3 7.31 0.65 7.76 0.23 
4 10.2 1.4 13.24 0.84 12.89 0.56 
6 14.33 1.2 16.23 0.92 17.24 0.78 
8 17.31 2.1 19.92 1.32 22.54 1.1 
10 22.14 2 24.79 1.84 28.61 1.21 
12 28.42 2.3 31.05 1.91 35.49 1.62 
14 31.85 2.1 34.57 2.13 38.8 1.95 
16 36.1 2.5 39.51 2.15 42.35 2.31 
18 41.51 3 43.62 2.3 48.21 2.12 
20 46.81 3.2 50.11 2.41 52.38 2.05 
22 51.93 3.3 55.18 2.13 58.17 2.65 
24 54.76 3.7 58.49 2.84 61.61 2.54 
26 60.25 3.65 62.78 3.12 66.84 2.15 
28 67.5 3.14 69.69 3.19 74.2 2.95 
30 72.42 4.58 76.13 3.68 78.92 3.02 
32 79.11 4.21 81.8 4.12 83.02 3.15 
34 88.23 4.87 90.2 3.85 92.11 3.17 
36 92.01 4.56 93.38 4.21 94.06 3.25 
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Table 4.11 In vitro percentage cumulative release profiles of different formulations of 
olanzapine PLGA microspheres with different polymer ratio 
Time 
Formulations 
F3 (200 mg) F5 (250 mg) F6 (300 mg) 
Days Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D 
0 0 0 0 0 0 0 
1 2.2 0.2 2 0.2 2.02 0.12 
2 4.12 0.5 3.61 0.8 3.1 0.31 
3 7.1 1.1 6.12 1.3 6.21 0.42 
4 12.14 1.4 10.2 1.4 8.14 0.35 
6 15.99 1.2 14.33 1.2 12.12 1.12 
8 19.3 1.6 17.31 2.1 16.35 1.01 
10 24.12 1.7 22.14 2 19.28 1.58 
12 30.01 2.4 28.42 2.3 24.21 1.95 
14 34.8 2.7 31.85 2.1 28.74 1.64 
16 39.1 3.1 36.1 2.5 31.2 2.12 
18 43.94 3 41.51 3 39.15 2.34 
20 48.79 3.4 46.81 3.2 41.81 2.58 
22 53.81 3.8 51.93 3.3 47.2 2.41 
24 58.02 4.1 54.76 3.7 52.31 2.98 
26 62.13 4.5 60.25 3.65 57.19 3.01 
28 68.76 4.3 67.5 3.14 60.8 3.25 
30 75.14 5.1 72.42 4.58 66.12 3.56 
32 81.2 5.2 79.11 4.21 74 3.87 
34 90.1 4.9 88.23 4.87 85.37 3.64 
36 93.51 4.8 92.01 4.56 88.11 3.98 
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Figure 4.5 In vitro release profiles of different formulations of olanzapine 
microspheres with different grades of PLGA 
 
Figure 4.6 In vitro release profiles of different formulations of olanzapine PLGA 
microspheres with different size distribution 
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Figure 4.7 In vitro release profiles of different formulations of olanzapine PLGA 
microspheres with different polymer ratio 
 
 
4.2.5 In vitro release kinetics 
To evaluate the release mechanism for olanzapine loaded PLGA microspheres different in 
vitro release models were applied. Percentage commutative  release  versus time data was 
applied to following mathematical model equations (Costa and Sousa Lobo, 2001): 
Zero Order kinetic model: Mt = Ko t 
Higuchi model:  Mt = KH t
1/2
 
Korsmeyer–Peppas:  Mt/M∞ = KKP t
n 
Hixson-Crowell:  (Wo)
1/3
 – (Wt)
1/3
 =KHC t 
Where Mt is % drug release at time t, Ko is kinetic rate constant for zero order model, KH 
is kinetic rate constant for Higuchi model, M∞ is % drug released at time ∞, KKP is kinetic 
rate constant for Korsmeyer-peppas model, Wo is initial amount of drug in dosage form, 
Wt is remaining amount of drug in dosage form at time t and KHC is kinetic rate constant 
for Hixson-Crowell model.  
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In vitro release kinetics of all formulations is shown in Table 4.12. In vitro release kinetic 
data shows that all the formulations have highest value for R
2
 for Korsmeyer-Peppas 
model which clearly indicates that release kinetic from olanzapine PLGA microspheres 
follow the Korsmeyer–Peppas release pattern. In Korsmeyer-Peppas model release 
mechanism is explained by value of n. The value of n=0.45 is for fickian diffusion or 
Case I, 0.45<n>0.89 is for non-fickian transport or anomalous transport, n= 0.89 is for 
Case II and n>0.89 is for Super Case II transport. In present study the value of n is in 
range from 0.701 to 1.021, which clearly indicates that release kinetic is following both 
non fickian diffusion and erosion of polymer. As in Case II the transport mechanism from 
polymer is associated with relaxation of polymer chains by water or biological fluid and 
generally described as erosion of polymer chain and anomalous transport (Peppas, 1984). 
Therefore the release of drug from olanzapine PLGA microspheres is by both non-fickian 
diffusion and erosion of PLGA polymer which is also indicated by SEM image of 
microspheres after placing in dissolution medium for 7 days as shown in Figure 4.8. Zero 
order kinetic model was second best fit model for all formulations of olanzapine loaded 
PLGA microspheres. 
 
 
Figure 4.8 SEM images of olanzapine loaded microsphere after placing in dissolution 
medium for 7 days 
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Table 4.12 In vitro release kinetics of different formulations of olanzapine loaded 
PLGA microspheres 
Model Parameter 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 
Zero order 
K0 3.37 3.094 2.511 1.968 2.426 2.261 2.533 2.644 
R
2 
0.9319 0.9764 0.9963 0.9875 0.9935 0.9861 0.9968 0.9974 
Higuchi 
KH 16.523 15.160 12.094 9.534 11.638 10.803 12.214 12.809 
R
2 
0.9477 0.9183 0.8464 0.8610 0.8283 0.8069 0.8516 0.8747 
Korsmeyer
-Peppas 
 
KKP 8.848 5.742 2.120 2.040 1.675 1.230 2.263 3.034 
R
2 
0.9887 0.9943 0.9972 0.9876 0.9973 0.9953 0.9972 0.9981 
n 0.701 0.810 0.881 0.883 0.887 0.893 0.885 1.021 
Hixson-
Crowell 
KHC 0.019 0.016 0.011 0.008 0.011 0.010 0.011 0.012 
R
2 
0.9872 0.9793 0.9590 0.9698 0.9518 0.9427 0.9612 0.9727 
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4.2.6 In vivo release of olanzapine PLGA microspheres 
Three selected formulations (F2, F3, F4) based on in vitro data were evaluated for their 
pharmacokinetic properties in rats and their plasma levels were determined at preset time 
intervals. The plasma concentration versus time curves were plotted for all three 
formulations as shown in Figure 4.9 & Table 4.13. The plasma concentration versus time 
curve data shows an initial burst release for all formulations as expected. Initial burst 
release was found in relation with ratio of lactic to glycolic acid in copolymer PLGA, 
microsphere size and bulk density. Initial burst was highest for F2 formulation and least 
for F4 formulation.  
Pharmacokinetic parameters were evaluated for all three formulations using a non-
compartment open model for extravascular dosage forms as shown in Table 4.14. Half life 
of formulations was increase as ratio of lactic to glycolic acid in copolymer and molecular 
weight of the polymer was increased. Increase in half life indicates a more sustained 
release of the drug from dosage form which in return decrease the  dosage  frequency 
(Vismari et al., 2002). Tmax for almost all formulation was reached within one hour due to 
initial burst release. MRT was increased from F2 to F4 showing a more sustained release 
trend. Cmax was decrease with increase as ratio of lactic to glycolic acid in copolymer and 
molecular weight of the polymer due to a decreased initial burst effect. Other 
pharmacokinetic parameters were also evaluated as shown in Table 4.14. Pharmacokinetic 
data reveals that Formulation F3 and F4 can be applied as potential one month release 
depot injection dosage form candidates.  
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
Table 4.13 Plasma concentrations (Mean ± S.D) at predefined time intervals of 
different formulations of olanzapine loaded microspheres 
Time 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
0 0.00 0.00 0.00 0.00 0.00 0.00 
1 5.03 0.57 3.13 0.37 0.90 0.71 
3 12.23 1.24 5.14 0.67 2.52 0.56 
5 19.97 2.26 7.37 1.13 5.25 1.44 
7 25.72 3.41 10.94 2.63 6.30 1.93 
10 32.42 4.63 15.42 3.60 8.37 1.99 
13 44.98 4.64 25.76 5.84 10.65 2.47 
16 58.65 8.61 28.76 6.59 14.33 3.34 
20 65.70 10.16 32.86 6.96 20.10 3.84 
25 67.73 8.95 43.66 7.27 24.47 4.57 
30 64.07 10.90 57.17 5.90 31.54 5.94 
35 58.17 9.03 53.49 6.91 41.72 6.56 
40 40.56 7.02 49.07 7.96 38.22 2.84 
45 17.38 6.81 32.73 4.53 33.92 3.89 
50 5.85 2.29 23.19 4.14 29.02 3.28 
60 0.00* 0.00* 17.66 2.62 24.97 3.36 
70 0.00* 0.00* 3.87 1.68 12.39 3.84 
80 0.00* 0.00* 0.00* 0.00* 5.86 1.86 
*Below the Lower Limit of Quantification 
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Figure 4.9 In vivo plasma concentration versus time curves for different formulations 
of olanzapine (20 mg/kg) loaded PLGA microsphere after subcutaneous 
injection 
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Table 4.14 Pharmacokinetic parameters of different formulations of olanzapine loaded 
microspheres 
Parameter Unit 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Mean ± S.D Mean ± S.D Mean ± S.D 
t1/2 d 1.72 0.26 5.32 0.98 6.65 0.24 
Tmax d 5.50 5.09 1.00 0.00 1.00 0.00 
Cmax ng/mL 101.82 5.60 69.48 7.40 55.58 4.66 
AUC 0-t ng/mL × d 1540.18 26.88 1093.96 68.73 1004.95 55.39 
AUC 0-inf ng/mL × d 1546.88 25.52 1143.02 72.42 1043.87 55.29 
AUMC 0-inf ng/mL × d
2
 14756.12 435.01 14357.45 961.17 15930.48 798.91 
MRT 0-inf d 9.54 0.18 12.56 0.37 15.26 0.24 
Vz/F (mg)/(ng/mL) 0.03 0.01 0.14 0.03 0.13 0.01 
Cl/F (mg)/(ng/mL)/d 0.01 0.00 0.02 0.00 0.02 0.00 
Where t1/2 is half life, Tmax is time for maximum concentration, Cmax is maximum plasma concentration, 
AUC is area under plasma vs time curve, AUMC area under mean plasma vs time curve, MRT is maximum 
residence time, Vz/F is apparent volume of distribution, Cl/F is apparent clearance, d=days and S.D is 
standard deviation.  
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4.3 Depot Parenteral Formulations Based on In Situ Gelling System 
4.3.1 PNA microgels based in situ gelling system 
Olanzapine loaded PNA microgels were successfully prepared with drug loading 
efficiency of 2.14 ± 0.52%. Loading efficiency was found low because of the nature of 
drug loading process, however the results were consistent with a previous study using 
same method of drug loading (Zhang et al., 2010a). Transmission electron microscopic 
studies revealed the morphology of olanzapine loaded PNA microgels as shown in Figure 
4.10. TEM study indicates the micron size of the PNA gel particles with spherical shape 
and slightly irregular outer surface.  
4.3.1.1 Viscosity measurements of olanzapine PNA microgels 
Viscosity of olanzapine PNA microgel dispersion was measured at pH 5.0 and pH 7.4, 
applying temperature range of 20-45°C as shown in Figure 4.11 and Table 4.15. The PNA 
microgels formulation is both pH and temperature sensitive, therefore showing a variable 
behavior in viscosity when temperature was increased on pH 7.4. At pH 7.4, viscosity was 
high even at 20°C, showing conversion to gel form on this pH value. Viscosity was 
decreased as temperature increases when measured in pH 5.0 dispersion. The nature in 
viscosity variation make this formulation favorable for injection from, as at pH 5.0 
injection will not turn into gel on room temperature or even at higher temperatures. The 
dual nature of microgel prevents clogging of syringe and premature gelation of 
formulation when compared with only temperature sensitive in situ gels. 
4.3.1.2 MTT cytotoxicity assay 
Olanzapine loaded PNA microgels did not show any significant sign of cytotoxicity when 
evaluated with MTT assay, as shown in Figure 4.12. A range of microgels concentrations 
(upto 50 mg/mL) were applied, but did not show a cytotoxic effect on any of the 
concentrations. After incubation for longer period (72 hours), there was little but no 
significant effect on metabolic proliferation of NH 3T3 cells. Alone MTT assay cannot 
predict the cytotoxicity of dosage form; further animals studies can predict the toxicity of 
PNA microgels.  
 
 
71 
 
 
Table 4.15 Viscosity Analysis of PNA microgels at different temperatures and pH 
Temperature 
Average Viscosity (mPa.s) 
 
pH-5.0 pH-7.4 
20 588 1125 
22 545 1105 
24 503 925 
26 445 915 
28 396 1012 
30 354 1025 
32 288 1050 
34 251 1015 
37 148 1095 
39 95 950 
42 15 815 
45 5 810 
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Figure 4.10 Transmission electron microscopic (TEM) image of olanzapine loaded 
PNA microgels 
 
Figure 4.11 Viscosity of olanzapine PNA microgel dispersion at various pH and 
temperature range 
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Figure 4.12 MTT assay of olanzapine loaded PNA microgels after incubation for 24 
hours and 72 hours 
 
4.3.1.3 In vitro release studies 
In vitro release profile of olanzapine from PNA microgels was observed on tissue 
conditions, as shown in Figure 4.13 & Table 4.16. In vitro release was characterized by a 
high initial burst release up to 38.6% of the drug release within two hours. This high 
initial burst release indicates that this dosage form might not be suitable for injectable 
dosage form due to potential of producing toxic effects. In vitro release pattern for 
olanzapine from PNA microgel was in consistent with in vitro release of other 
hydrophobic drugs from microgels in a previous study (Zhang et al., 2010a). This initial 
release was followed by a sustained release phase, which lasted for 50 hours. Release 
mechanism was best described by Korsmeyer-Peppas model (r
2
 = 0.9681, n = 0.397), n 
value indicates that release of olanzapine from PNA microgels was controlled by fickian 
diffusion (Costa and Sousa Lobo, 2001).  
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Table 4.16 In vitro percentage cumulative release profiles of olanzapine from PNA 
microgels 
Time Percentage cumulative release 
Hours Mean (%) ± S.D 
0 0.0 0.0 
1 2.0 0.2 
2 3.61 0.8 
4 6.12 1.3 
8 10.2 1.4 
12 14.33 1.2 
14 17.31 2.1 
16 22.14 2.0 
18 28.42 2.3 
22 31.85 2.1 
24 36.1 2.5 
28 41.51 3.0 
30 46.81 3.2 
32 51.93 3.3 
34 54.76 3.7 
40 60.25 3.65 
45 67.5 3.14 
50 72.42 4.58 
60 79.11 4.21 
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Figure 4.13 In vitro release profile of olanzapine from PNA microgels observed on 
tissue conditions 
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4.3.1.4 In vivo studies of Olanzapine loaded PNA microgels  
In vivo release of subcutaneous injection of olanzapine loaded PNA microgels was 
compared with oral olanzapine. In vivo release data indicates an initial high burst release 
from the subcutaneous injection of PNA microgels but this initial burst release was 
followed by a sustained release for 72 hours (Figure 4.14 & Table 4.17). Oral dose of 
olanzapine also provided an initial rapid absorption but plasma levels were maintained for 
only 24 hours (Figure 4.14). PNA microgels can be formulated for short term depot 
injection, which can potentially provide the release of olanzapine for 72 hours. 
Pharmacokinetic parameters were evaluated for both oral olanzapine and olanzapine 
loaded PNA microgels as described in Table 4.18. Half life of the in situ gel (8.66 ± 0.18) 
was higher as compared to oral olanzapine (2.54 ± 0.15), which indicates a more 
sustained release pattern of olanzapine from PNA microgels (Vismari et al., 2002). Mean 
residence time (MRT) was also higher for PNA microgels when compared with oral 
olanzapine. Area under the plasma versus time curves (AUC) for subcutaneous injection 
of PNA microgels was higher as compared to oral olanzapine because subcutaneous rout 
of administration provides better bioavailability than oral route (Jundt et al., 1993). When 
pharmacokinetic parameters were compared statistically, all parameters were having 
highly significant difference except Tmax (time for maximum plasma concentration). Tmax 
for oral olanzapine and PNA microgels of olanzapine was found with non-significant 
difference, which indicates that sustained formulation was exhibiting an initial burst 
release comparable with oral absorption. 
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Table 4.17 Plasma concentrations (Mean ± S.D) at predefined time intervals of 
olanzapine in rats (n=6) after oral dose of olanzapine (7 mg/kg) and 
subcutaneous dose of PNA microgels of olanzapine (7 mg/kg) 
Time (hours) 
Olanzapine oral dose PNA microgels of olanzapine 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
0 0 0 0 0 
0.5 219.33 15.25 160.96 9.56 
1 412.58 40.23 226.58 25.31 
3 200.67 20.48 179.25 17.54 
6 116.71 12.54 140.76 18.21 
12 33.29 5.47 90.38 8.51 
24 0.75 0.273 52.93 7.43 
36 0.00* 0.00 31.15 6.12 
48 0.00* 0.00 14.98 2.65 
60 0.00* 0.00 6.18 2.01 
72 0.00* 0.00 0.00* 0.00 
*Below the Lower Limit of Quantification 
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Table 4.18 Non-compartmental pharmacokinetic parameters of olanzapine (Mean ± 
S.D) in rats (n=6) after oral dose of olanzapine (7 mg/kg) and 
subcutaneous dose of PNA microgels of olanzapine (7 mg/kg) 
Parameter Unit 
Olanzapine 
(Oral) 
PNA microgels 
of Olanzapine 
P-value 
Difference 
based on 
P-value 
Mean ± S.D Mean ± S.D 
t1/2 h 2.54 0.15 8.66 0.18 <0.001 
highly 
significant 
Tmax h 1 5.09 1.33 0.82 0.36322 
non  
significant 
Cmax ng/mL 412.7 18.7 226.58 10.08 <0.001 
highly 
significant 
AUC 0-t 
ng/mL 
× h 
1956.7 119.2 3522.90 226.90 <0.001 
highly 
significant 
AUC 0-inf 
ng/mL 
× h 
1959.5 119.5 3525.20 227.39 <0.001 
highly 
significant 
MRT 0-inf h 4.6 0.08 16.24 0.26 <0.001 
highly 
significant 
Where t1/2 is half life, Tmax is time for maximum concentration, Cmax is maximum plasma concentration, 
AUC is area under plasma vs time curve, MRT is maximum residence time, h=hours and S.D is standard 
deviation.  
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Figure 4.14 In vivo release profile of olanzapine from oral olanzapine (7 mg/kg) 
and subcutaneous PNA microgels (7 mg/kg) in rats (n=6) 
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4.3.2 Phase sensitive PLGA based in situ gelling system 
4.3.2.1 In vitro release of olanzapine in situ gelling implant  
In vitro release profiles from olanzapine loaded in situ implants with different PLGA 
grades and concentrations are shown in Figure 4.15 & Figure 4.16, respectively and 
tabulated in Table 19 & Table 20. Release profiles indicate an initial burst release from all 
formulation but the phenomenon of initial burst release was decreased as ratio of lactide 
to glycolide in copolymer PLGA was increased. Initial burst release is dependent on the 
lag time in which liquid solution formulation turn into solid gel form. During the lag time, 
the drug along with solvent diffuse out in the medium resulting in burst release. Increase 
in polymer concentration also had decreasing effect on initial burst release from in situ 
gel implant. Increasing molecular weight and concentration of polymer to control initial 
burst release is also reported in previous literature (Hatefi and Amsden, 2002). NMP as a 
solvent was used in this study because DAMSO as a solvent is causing a higher initial 
burst release (Ahmed et al., 2012). Initial burst release was followed by a slow or 
sustained release and this sustained release pattern was also affected by the polymer type 
and concentration of polymer. Increase in polymer concentration and lactide to glycolide 
ratio in PLGA copolymer resulted in more delayed release. In vitro release from 
formulation batch F4 (PLGA 85:15, 40% w/v) was slowest whereas release from 
formulation batch F6 (PLGA 75:25, 20% w/v) and batch F1 (PLGA 50:50, 40 % w/v) was 
fastest of all formulations. The release of drug from in situ gel implant was also affected 
by solubility of the drug as olanzapine is practically insoluble drug in water having a 
more delayed release profile as compared to water soluble drugs (Jeong et al., 2000). 
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Table 4.19 In vitro percentage cumulative release profile of olanzapine in situ gel 
implant formulations with different lactide to glycolide ratio in PLGA 
Time 
Formulations 
F1 (PLGA 50:50) F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
Mean 
(%) 
± S.D 
0 0 0 0 0 0 0 0 0 
1 19.87 3.45 13.94 2.12 12.04 2.11 10.23 3.1 
2 23.74 0.68 15.82 0.45 13.85 1.02 13.14 1.12 
3 28.71 1.12 18.71 0.62 17.14 0.68 14.87 0.44 
5 33.91 1.42 22.68 0.71 19.54 0.74 17.96 0.64 
7 37.45 1.51 25.42 0.86 24.08 0.65 22.31 0.75 
10 47.12 2.01 38.02 1.21 34.75 1.1 29.4 0.81 
13 61.87 2.12 47.11 1.35 41.25 1.41 36.76 1.12 
16 69.23 2.45 51.91 1.32 47.91 1.52 43.08 1.87 
19 78.51 2.64 59.67 1.48 53.76 1.61 49.74 1.42 
21 84.11 2.74 64.21 1.46 57.81 1.51 52.26 1.32 
24 92.2 2.91 69.54 1.58 63.24 1.74 57.43 1.94 
27 100.12 3.12 75.85 2.12 69.41 1.85 63.28 1.96 
30   87.31 2.34 77.84 1.92 67.96 2.11 
33   94.53 2.46 85.73 2.11 78.79 2.13 
36   99.89 2.81 94.05 2.21 87.25 2.74 
39     100.11 3.4 94.98 3.14 
42       99.76 3.84 
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Table 4.20 In vitro percentage cumulative release profile of olanzapine in situ gel 
implant formulations with different concentrations of polymer (PLGA) 
Time 
Formulations 
F3 (PLGA 40%) F5 (PLGA 30%) F6 (PLGA 20%) 
Days Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D 
0 0 0 0 0 0 0 
1 12.04 2.11 14.85 3.64 22.14 5.8 
2 13.85 1.02 18.14 1.12 28.31 1.2 
3 17.14 0.68 20.76 0.74 34.11 0.81 
5 19.54 0.74 26.84 0.62 38.87 0.64 
7 24.08 0.65 36.31 1.13 45.84 1.25 
10 34.75 1.1 45.19 1.24 53.4 1.51 
13 41.25 1.41 54.37 1.31 62.33 1.81 
16 47.91 1.52 59.89 1.48 67.41 2.15 
19 53.76 1.61 65.01 1.34 74.83 2.68 
21 57.81 1.51 68.94 1.67 83.32 3.11 
24 63.24 1.74 77.35 1.84 93.41 3.14 
27 69.41 1.85 84.83 2.17 99.78 3.88 
30 77.84 1.92 95.88 2.56 100 0.00 
33 85.73 2.11 99.78 3.15   
36 94.05 2.21 100 0.00   
39 100.11 3.4     
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Figure 4.15 In vitro release profile of olanzapine in situ gel implant formulations with 
different lactide to glycolide ratio in PLGA 
 
 
Figure 4.16 In vitro release profile of olanzapine in situ gel implant formulations with 
different concentrations of polymer (PLGA) 
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4.3.2.2 In vitro release kinetics  
In vitro release kinetics for olanzapine from in situ gel implant was evaluated by applying 
different release models. Release kinetics were determined by using following 
mathematical model equations (Costa and Sousa Lobo, 2001): 
Zero Order kinetic model: Mt = Ko t 
Higuchi model:  Mt = KH t
1/2
 
Korsmeyer–Peppas:  Mt/M∞ = KKP t
n 
Hixson-Crowell:  (Wo)
1/3
 – (Wt)
1/3
 =KHC t 
Where Mt is % drug release at time t, Ko is kinetic rate constant for zero order model, KH 
is kinetic rate constant for Higuchi model, M∞ is % drug released at time ∞, KKP is kinetic 
rate constant for Korsmeyer-peppas model, Wo is initial amount of drug in dosage form, 
Wt is remaining amount of drug in dosage form at time t and KHC is kinetic rate constant 
for Hixson-Crowell model.  
Release kinetics parameters were calculated by using DDSolver, a Microsoft Excel based 
add on program (Zhang et al., 2010b). Parameters for release kinetics calculated from 
different mathematical dissolution models are shown in Table 4.21. All formulations seem 
to follow the release model of Korsmeyer-Peppas as all formulations had the highest 
values for R
2 
in this model. Mechanism of drug release from drug delivery system is 
explained by the value of n in Korsmeyer-Peppas model. The value of n=0.45 for fickian 
diffusion or Case I, 0.45<n>0.89 for non-fickian transport or anomalous transport, n= 
0.89 for Case II and n>0.89 for Super Case II transport. The value of n of all formulations 
fell within the range of 0.51 to 0.83 which indicates the release pattern of Case II. As 
release of drug from formulation is Case II, the pattern is described as relaxation of 
polymer chains by biological fluids and erosion of polymer causing a non-fickian or 
anomalous transport (Peppas, 1984).  
 
 
 
 
 
 
85 
 
Table 4.21 In vitro release kinetics of PLGA based olanzapine in situ gel formulations 
Model Parameter 
Formulations 
F1 F2 F3 F4 F5 F6 
Zero order 
K0 4.096 2.956 2.669 2.432 3.317 4.127 
R
2
 0.8893 0.9552 0.9675 0.9771 0.9179 0.7867 
Higuchi 
KH 17.748 14.551 13.626 12.823 15.774 18.086 
R
2
 0.9725 0.9437 0.9332 0.9151 0.9700 0.9849 
Korsmeyer–
Peppas 
KKP 12.888 6.989 5.675 4.364 10.046 17.411 
R
2
 0.9872 0.9909 0.9916 0.9895 0.9937 0.9852 
n 0.614 0.736 0.774 0.829 0.650 0.514 
Hixson-
Crowell 
KHC 0.022 0.015 0.013 0.012 0.018 0.023 
R
2
 0.9547 0.9712 0.9708 0.9648 0.9712 0.9111 
 
 
4.3.2.3 Scanning electron microscopic studies 
Figure 4.17 shows the internal structure of in situ implant from batch 3 (PLGA 75:25, 
40% w/v) after longitudinal cut. Scanning electron microscopic study indicates a porous 
internal structure similar to a gel. The porous internal structure was formed due to 
immediate diffusion of phosphate buffer inside upon injection of polymer drug solution 
and this porous nature facilitates the drug release from the implant (Fredenberg et al., 
2011).  
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4.3.2.4 FTIR and viscosity analysis 
FTIR spectra of PLGA (75:25), olanzapine and formulation batch 3 (PLGA 75:25, 40% 
w/v) is shown in Figure 4.18. Characteristic peaks of PLGA and olanzapine were 
observed which indicated that there was no or little polymer drug interaction found in 
formulations. Viscosity analysis for liquid formulation was evaluated to predict the 
suitability for injection. Viscosity of all formulations was in range from 269 to 458 mPa.s, 
as shown in Table 4.22. Viscosity of all formulations was within the limits for suitability 
in injection form, which is 15-500 mPa.s (Stoy and Chvapil, 1986). Viscosity of 
formulation solutions was increased with increase in polymer concentration, molecular 
weight and ratio of lactide to glycolide in PLGA.  
 
Table 4.22 Viscosity of different formulation batches of PLGA based olanzapine in 
situ implant gel 
Formulation PLGA 
Conc. of PLGA in NMP 
w/v (%) 
Drug Loading 
w/v (%) 
Viscosity* 
mPa.s 
F1 50:50 40 5 352±20.14 
F2 65:35 40 5 375±24.36 
F3 75:25 40 5 394±20.89 
F4 85:15 40 5 458±34.58 
F5 75:25 30 5 306±19.14 
F6 75:25 20 5 269±14.71 
*Viscosity of formulation is taken as average of three ± standard deviation and measured at 25°C on shear 
rate of 100s
-1
. 
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Figure 4.17 Cross section scanning electron microscopic image of in situ gel implant 
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Figure 4.18 FTIR spectra of (A) PLGA, (B) olanzapine and (C) in situ gel implant 
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4.3.2.5 In vivo release studies and pharmacokinetic analysis 
Three formulations (F2, F3 and F4) were selected for in vivo studies based on their in 
vitro release data. Formulation with more sustained release and less initial burst release 
were selected as to develop an in situ gel implant for 30 days of dosage interval. A dose of 
25 mg/kg was injected into subcutaneous tissue of the rat using NMP as vehicle solvent. 
NMP is commercially used in FDA approved injectable dosage forms for human use 
(Dong et al., 2006). A plasma concentration versus time curves was developed for each 
formulation as shown in Figure 4.19 & Table 4.23. Plasma concentration data shows an 
initial burst release for all formulations as expected from in vitro data. Initial burst release 
was highest for formulation F2 and lowest for F4 which indicates that increasing 
molecular weight and lactide to glycolide ratio in PLGA show a decrease in initial burst 
release. Except for formulation F2 both formulations F3 and F4 showed a sustained 
release pattern for over 30 days. 
Pharmacokinetic parameters were calculated from plasma concentration versus time 
curves as shown in Table 4.24. Pharmacokinetic data revealed that Cmax for all 
formulations was reached within first day of administration due to initial burst release 
effect. Cmax for formulation F2, F3 and F4 was 121.53, 81.64 and 54.39 ng/mL, 
respectively. MRT and half life of the formulations increase with increase in molecular 
weight and lactide to glycolide ratio in PLGA, showing an incremental sustained release 
effect. If olanzapine  rat plasma levels are compared with human plasma levels then 
formulations F3 and F4 were found within the therapeutic range for at least 30 days as 
therapeutic range of olanzapine for human is from 9 to 80 ng/mL (Kopitz, 2004; Der 
Agnp Federführend et al., 2001). A plasma concentration of over 80 ng/mL was observed 
for formulation F2 which could have the potential of toxic adverse effects. Other 
pharmacokinetic parameters are described in Table 4.24.  
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Table 4.23 Plasma concentrations (Mean ± S.D) at predefined time intervals of 
different formulations of in situ gel of olanzapine 
Time 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
0 0.00 0.00 0.00 0.00 0.00 0.00 
0.125 20.94 1.56 12.55 2.75 10.30 1.39 
1 119.93 14.58 81.64 5.90 53.80 4.13 
2 110.28 8.18 61.62 5.87 53.93 3.79 
3 100.72 6.97 54.79 3.66 50.54 4.01 
5 70.75 9.25 50.65 3.79 50.63 3.35 
7 50.27 7.75 47.50 3.75 48.68 2.48 
10 39.29 5.11 44.43 2.84 46.24 3.15 
13 23.85 2.54 32.38 2.19 37.35 2.32 
16 12.89 1.66 25.97 2.07 30.00 2.21 
20 6.37 1.17 22.19 3.33 24.26 2.34 
24 0.35 0.86 15.61 0.92 19.45 1.71 
28 0.00* 0.00* 12.09 0.68 17.08 1.56 
32 0.00* 0.00* 9.51 0.44 10.80 1.30 
36 0.00* 0.00* 2.96 0.86 5.84 1.02 
*Below the Lower Limit of Quantification 
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Figure 4.19 Plasma concentrations versus time curves of different formulation of in 
situ gel of olanzapine (25 mg/kg) after subcutaneous injection in rats 
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Table 4.24 Pharmacokinetic Parameters of different formulation of in situ gel of 
olanzapine (25 mg/kg) after subcutaneous injection in rats 
Parameter Unit 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Mean ± S.D Mean ± S.D Mean ± S.D 
t1/2 d 3.80 0.75 5.16 0.35 9.15 0.43 
Tmax d 1.33 0.52 1.00 0.00 1.50 0.55 
Cmax ng/mL 121.53 13.57 81.64 5.38 54.39 4.02 
AUC 0-t ng/mL × d 901.89 77.03 1011.51 68.52 1062.11 73.02 
AUC 0-inf ng/mL × d 932.29 73.71 1050.97 78.30 1106.09 82.96 
AUMC 0-inf ng/mL × d
2
 6318.48 573.03 13839.67 1361.60 15709.58 1578.32 
MRT 0-inf d 6.78 0.37 13.15 0.40 14.18 0.43 
Vz/F (mg)/(ng/mL) 0.15 0.04 0.32 0.02 0.17 0.01 
Cl/F (mg)/(ng/mL)/d 0.03 0.02 0.02 0.02 0.02 0.02 
Where t1/2 is half life, Tmax is time for maximum concentration, Cmax is maximum plasma concentration, 
AUC is area under plasma vs time curve, AUMC area under mean plasma vs time curve, MRT is maximum 
residence time, Vz/F is apparent volume of distribution, Cl/F is apparent clearance, d=days and S.D is 
standard deviation.  
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4.4 Depot Parenteral Formulations Based Solid PLGA Implant 
4.4.1 In vitro release study 
In vitro release of surgically implantable olanzapine loaded PLGA cylinders was affected 
by changing the ratio of lactide to glycolide ratio in PLGA and initial drug loading. 
Impact on release pattern of implant formulation by changing ratio of lactide to glycolide 
in PLGA is shown in Figure 4.20 and Table 4.25. All formulations showed a tri-phase 
release pattern: first phase was characterized as slow release for almost 10 days, initial 
slow release was followed by a second rapid release phase almost between 11 to 40 days 
and another slow release phase (third phase) until drug completely dissolved. This three 
phase release pattern was also described in previous studies using haloperidol (Wang et 
al., 2010; Metzger et al., 2007; Siegel et al., 2006). Initial release at 11 day for 50:50, 
65:35, 75:25 and 85:15 PLGA based implant was 8.9, 7.32, 6.19 and 3.25%, respectively. 
This data shows that release from olanzapine PLGA implant was decreased as the lactide 
to glycolide ratio in PLGA was increased and similar results have been reported in a 
previous study with risperidone (Rabin et al., 2008). In vitro release profiles by changing 
initial drug loading was also studied as shown in Figure 4.21 and Table 4.26. In vitro 
release profiles slightly differ as the initial drug loading was increased from 20% to 30% 
and 40%. Initial release for olanzapine loaded PLGA (75:25) implants at 11 day for 20, 30 
and 40% drug loading was 2.43, 2.91 and 6.19%, respectively. In second phase of drug 
release from implant, the rate of drug release was increased as drug loading was 
decreased. The change of release pattern with dug loading was possibly a result of 
increased ratio of hydrophobic drug and decreased hydrophilicity of implant formulation 
(Wang et al., 2010).  
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Table 4.25 In vitro percentage cumulative release profile of olanzapine implant 
formulations with different lactide to glycolide ratio in PLGA 
Time 
Formulations 
F1 (PLGA 50:50) F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D 
0 0 0 0 0 0 0 0 0 
1 4.91 0.41 3.41 0.21 2.83 0.18 1.52 0.17 
3 5.87 0.53 4.52 0.32 3.37 0.19 1.89 0.21 
5 6.7 0.74 5.57 0.51 4.79 0.29 2.14 0.23 
7 6.9 1.2 5.89 0.85 5.14 0.34 2.58 0.28 
9 7.14 1.5 6.12 1.02 5.83 0.87 2.96 0.31 
11 8.9 1.4 7.32 1.05 6.19 0.96 3.25 0.39 
13 13.65 2.3 10.59 1.21 8.72 1.12 5.7 0.48 
15 29.41 3.4 19.57 2.11 15.93 1.87 8.94 1.13 
17 44.88 2.9 30.35 2.18 25.3 2.15 10.56 1.45 
19 57.05 3.21 40.87 2.42 31.48 2.01 19.56 1.46 
21 68.91 3.42 52.13 2.54 40.82 2.31 28.65 1.74 
23 77.13 4.56 60.39 2.89 51.57 2.45 35.48 1.81 
25 83.05 4.87 71.41 3.51 58.02 2.56 45.12 1.69 
27 86.93 5.1 76.33 3.86 62.11 2.71 50.23 1.53 
29 91.2 4.96 80.5 4.02 68.08 2.85 55.78 2.05 
31 93.16 4.85 84.27 4.16 70.94 3.12 59.64 2.11 
33 94.97 5.12 87.58 4.82 74.13 3.02 61.97 2.15 
35 97.01 3.17 89.7 4.72 76.17 2.96 65.02 2.31 
37 99 2.86 93.61 4.53 79.85 3.65 67.05 2.65 
39 100 0.91 95.68 4.11 82.06 3.41 71.51 2.14 
41   96.57 4.62 84.08 3.52 74.61 2.68 
43   98.41 2.31 84.94 2.98 76.24 2.43 
45   99.02 1.14 86.93 3.69 78.14 2.19 
47   99.7 0.31 89.24 2.96 79.63 1.96 
49   100 0.68 91.31 3.41 81.87 2.65 
51     93.16 2.12 83.73 2.7 
53     95.06 2.51 85.59 2.1 
55     96.3 1.96 86.83 2.65 
57     97.18 1.58 88.19 3.56 
59     98.42 0.97 90.22 3.11 
60     99.08 0.96 91.65 1.96 
70     100 0 95.6 1.58 
80       100 0 
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Table 4.26 In vitro percentage cumulative release profile of olanzapine (OLZ) implant 
formulations with different initial drug loading (% w/w of polymer) 
Time 
Formulations 
F3 (OLZ 40%) F5 (OLZ 30%) F6 (OLZ 20%) 
Days Mean (%) ± S.D Mean (%) ± S.D Mean (%) ± S.D 
0 0 0 0 0 0 0 
1 2.83 0.18 0.81 0.08 0.48 0.04 
3 3.37 0.19 0.89 0.06 0.67 0.05 
5 4.79 0.29 1.48 0.09 0.91 0.03 
7 5.14 0.34 2.6 0.16 1.56 0.11 
9 5.83 0.87 2.78 0.21 2.05 0.16 
11 6.19 0.96 2.91 0.25 2.43 0.54 
13 8.72 1.12 10.54 0.28 9.74 0.41 
15 15.93 1.87 18.96 0.62 20.54 2.56 
17 25.3 2.15 30.64 3.58 35.12 2.84 
19 31.48 2.01 38.91 4.57 51 3.12 
21 40.82 2.31 58.76 4.89 62.31 3.24 
23 51.57 2.45 63.41 3.87 71.22 4.51 
25 58.02 2.56 67.94 5.12 74.97 4.62 
27 62.11 2.71 71.89 4.32 78.79 3.11 
29 68.08 2.85 77.62 3.89 84.05 2.96 
31 70.94 3.12 80.31 3.14 89.11 2.81 
33 74.13 3.02 85.14 2.86 91.99 2.23 
35 76.17 2.96 87.64 2.45 93.08 1.92 
37 79.85 3.65 89.65 2.05 95.4 1.85 
39 82.06 3.41 93.18 1.92 98 0.43 
41 84.08 3.52 94.87 1.84 98.7 0.31 
43 84.94 2.98 96.74 1.76 99.13 0.14 
45 86.93 3.69 98.12 1.25 100 0.23 
47 89.24 2.96 99.64 0.74   
49 91.31 3.41 100 0.81   
51 93.16 2.12     
53 95.06 2.51     
55 96.3 1.96     
57 97.18 1.58     
59 98.42 0.97     
60 99.08 0.96     
70 100 0     
80       
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Figure 4.20 In vitro release profile of olanzapine implant formulations with different 
lactide to glycolide ratio in PLGA 
 
 
Figure 4.21 In vitro release profile of olanzapine (OLZ) implant formulations with 
different initial drug loading (% w/w of polymer) 
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4.4.2 Drug loading and efficiency of entrapment 
Actual drug loading of implant batches ranged from 19.61±0.4% to 40.23±1.02% 
and efficiency of entrapment of drug ranged from 97.07% to 100.58%.  Actual 
drug loading and efficiency of entrapment of drug in implant was found 
satisfactory as shown in Table 4.27.    
 
 
Table 4.27 Loading and efficiency of different formulation batches of olanzapine 
loaded PLGA implant  
Formulation PLGA 
Olanzapine w/w 
(%) 
Actual Drug Loading 
(%) 
Efficiency (%) 
Mean ± S.D 
F1 50:50 40 39.23 ± 0.74 98.08 
F2 65:35 40 38.96 ± 0.63 97.40 
F3 75:25 40 40.23 ± 1.02 100.58 
F4 85:15 40 39.57 ± 0.58 98.93 
F5 75:25 30 29.12 ± 0.87 97.07 
F6 75:25 20 19.61 ± 0.4 98.05 
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4.4.2 In vitro release kinetic studies 
To evaluate the release mechanism for olanzapine loaded PLGA implant, different in vitro 
release models were applied. In general, four major release models are applied for 
studying drug release mechanism and mathematical model equations for these models are 
given below (Costa and Sousa Lobo, 2001): 
Zero Order kinetic model: Mt = Ko t 
Higuchi model:  Mt = KH t
1/2
 
Korsmeyer–Peppas:  Mt/M∞ = KKP t
n 
Weibull model:          
       
 
 
  
Where Mt is % drug release at time t, Ko is kinetic rate constant for zero order model, KH 
is kinetic rate constant for Higuchi model, M∞ is % drug released at time ∞, KKP is kinetic 
rate constant for Korsmeyer-peppas model, Ti is lag time before onset of dissolution, a is 
the time scale of the process and b is the shape parameter of the curve. 
In vitro release kinetic parameters were calculated for all formulations with these four 
models as shown in Table 4.28. In vitro release kinetic parameters using dissolution 
models were calculated with the help of DDSolver, a Microsoft Excel based add on 
program (Zhang et al., 2010b). Weibull model had the highest value of R
2
 for all 
formulations, which indicates that release mechanism can be best explained by this 
model. Value of b in Weibull model explains the mechanism of release, as the Case I (b = 
1) has exponential curve with release obeying Fick’s first law of diffusion, Case II (b > 1) 
has sigmoidal curve with complex release mechanism and Case III (b < 1) has parabolic 
curve with diffusion controlled release or with contribution of another release mechanism 
(Papadopoulou et al., 2006). In this study, value of b is b > 1 for all formulations, which 
indicates that the release curve is sigmoidal and the release mechanism is complex. Value 
of Ti is not zero and greater than 7 for all formulations, which indicates the presence of a 
lag time for the onset of dissolution.  
4.4.3 Surface morphology and FTIR analysis 
SEM image of olanzapine loaded implant showed a very smooth surface as shown in 
Figure 4.22(A). The implant removed from the dissolution medium after 7 days showed a 
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porous and eroded surface as shown in Figure 4.22(B). Surface morphology indicates that 
release of olanzapine may be due to pores formed on the surface of implant and by 
erosion and degradation of polymer. FTIR spectra of olanzapine, PLGA and implant 
formulation indicated that there was slight or no drug interaction with polymer was 
present in implant formulation as shown in Figure 4.23. 
4.4.4 XRD and DSC analysis 
X-ray diffractometric pattern of olanzapine, PLGA and olanzapine loaded PLGA implant 
is shown in Figure 4.24. XRD pattern indicates that PLGA has an amorphous nature with 
several peaks; olanzapine has a crystalline nature with sharp peaks and implant pattern 
showed a decrease in crystalline nature of olanzapine. Similar results of decrease in 
crystallinity of the drug, when formulated with PLGA were also found in previous studies 
(Shaikh et al., 2009; Abdelwahed et al., 2006).  
Thermograms of olanzapine, PLGA and implant formulation is shown in Figure 4.25. 
Endothermic peak of olanzapine was found at 195.2°C showing its crystalline nature, 
whereas endothermic peak of PLGA was observed at 60.02°C indicating its amorphous 
nature and glass transition temperature. Implant thermogram revealed the broadening 
olanzapine peak and a negative shifting of PLGA endothermic peak. Negative shifting 
may indicate a physical interaction such as hydrogen bonding between drug and polymer 
(Feldstein et al., 2001). 
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Table 4.28 In vitro release kinetics of PLGA based olanzapine implant formulations 
Model Parameter 
Formulations 
F1 F2 F3 F4 F5 F6 
Zero order 
K0 2.814 2.338 1.826 1.563 2.291 2.508 
R
2 
0.9199 0.9297 0.9210 0.9238 0.9262 0.9093 
Higuchi 
KH 14.012 13.114 11.829 10.346 12.812 13.399 
R
2 
0.7341 0.7681 0.8241 0.7902 0.7556 0.7307 
Korsmeyer–
Peppas 
 
KKP 1.589 1.922 2.967 1.991 1.688 1.606 
R
2 
0.9292 0.9308 0.9296 0.9259 0.9289 0.9148 
n 1.170 1.055 0.873 0.938 1.085 1.127 
Weibull 
 
a 100.520 151.288 33.838 29.734 28.540 16.978 
b 1.816 1.798 1.220 1.105 1.298 1.228 
Ti 7.685 7.512 10.154 12.559 10.609 11.652 
R
2
 0.9926 0.9958 0.9954 0.9961 0.9968 0.9986 
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Figure 4.22 Scanning electron microscopic image of surface of implant before 
dissolution (A) and after 7 days in dissolution medium (B) 
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Figure 4.23 FTIR spectra of olanzapine, PLGA and implant formulation 
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Figure 4.24 X-ray diffractrometric pattern of olanzapine, PLGA and implant 
formulation 
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Figure 4.25 DSC thermograms of olanzapine, PLGA and implant formulation 
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4.4.5 In vivo release and pharmacokinetic studies 
Three formulations F2, F3 and F4 with 65:35, 75:25 and 85:15 lactide to glycolide ratio 
in PLGA, respectively and with 40 wt% drug loads, were evaluated for in vivo studies on 
the basis of in vitro release data. Plasma concentration versus times curves of these 
formulations after surgical implantation of olanzapine (60 mg/kg) loaded PLGA cylinder 
is shown in Figure 4.26 & Table 4.29. In vivo plasma concentration data shows less initial 
plasma levels of olanzapine with peak levels for 21 to 37 days and this plasma 
concentration data is in accordance with the in vitro release data with initial lag time for 
dissolution. This lag time in the release of drug may be due to hydration of formulation 
during this period (Wang et al., 2010). The initial release from implant is far much less 
than other formulations of olanzapine like microspheres for depot parenteral injection 
having an initial burst release (D’souza et al., 2013). Sufficient plasma levels were 
obtained for the approximate period of 45, 60 and 70 days for F2, F3 and F4, respectively. 
Data suggests that as the ratio of lactide to glycolide in PLGA is increased, the in vivo 
release from the implant is more delayed. 
Pharmacokinetic parameters were calculated from plasma concentration versus time data, 
as summarized in Table 4.30. Values for half life (t1/2) and mean residence time (MRT) 
were increased with increase in the ratio of lactide to glycolide in PLGA polymer, 
suggesting a more sustained release pattern. Maximum plasma concentration (Cmax) was 
decreased with increase in the ratio of lactide to glycolide in PLGA polymer. Other 
pharmacokinetic paramteres were also observed as described in Table 4.28. In vivo 
implant removal was also performed with ease and success to stop treatment at any time, 
showing its good applicability as implant dosage form. In vivo plasma concentration and 
pharmacokinetic data indicates that such implant formulation could be a potential dosage 
form to release the olanzapine over a period of 70 days. 
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Table 4.29 Plasma concentrations (Mean ± S.D) at predefined time intervals of 
different formulations of olanzapine loaded implant 
Time 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Days 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
Mean 
(ng/mL) 
± S.D 
0 0.00 0.00 0.00 0.00 0.00 0.00 
0.125 50.15 5.44 30.22 2.96 25.43 2.31 
1 98.03 7.34 69.48 7.40 55.58 4.66 
2 91.87 6.56 55.72 4.58 37.92 3.46 
4 80.37 5.86 47.43 4.20 34.40 2.16 
6 85.97 7.15 53.82 4.78 35.40 2.23 
8 83.88 7.37 60.83 5.01 37.28 1.67 
10 90.10 9.71 55.75 3.15 40.15 2.09 
12 88.18 9.03 49.88 3.54 42.10 1.71 
14 69.58 5.75 40.68 2.84 36.38 1.96 
16 57.50 3.88 32.43 2.44 33.85 2.23 
18 37.75 3.55 27.72 1.31 29.35 2.58 
20 25.27 2.88 24.15 1.44 26.95 1.80 
22 16.08 1.74 20.82 0.90 25.22 1.87 
24 6.13 0.62 15.72 0.58 23.23 1.52 
26 3.03 0.26 13.58 0.60 21.30 1.37 
28 0.17 0.41 11.47 0.60 19.22 1.14 
30 0.00* 0.00* 7.80 0.31 13.92 0.67 
32 0.00* 0.00* 5.97 0.28 11.38 0.67 
36 0.00* 0.00* 0.00* 0.00* 5.80 0.24 
*Below the Lower Limit of Quantification 
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Figure 4.26 Plasma concentrations versus time curves of different formulation of 
PLGA implants of olanzapine (60 mg/kg) after implantation in rats 
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Table 4.30 Pharmacokinetic Parameters of different formulation of olanzapine (60 
mg/kg) loaded PLGA implant after implantation in rats 
Parameter Unit 
Formulations 
F2 (PLGA 65:35) F3 (PLGA 75:25) F4 (PLGA 85:15) 
Mean ± S.D Mean ± S.D Mean ± S.D 
t1/2 d 3.53 0.39 9.50 0.82 9.63 1.29 
Tmax d 21.67 2.58 29.17 1.86 36.67 2.58 
Cmax ng/mL 74.14 3.22 58.56 2.70 43.90 3.00 
AUC 0-t ng/mL × d 2123.44 157.82 1979.65 71.77 1700.39 104.24 
AUC0-inf ng/mL × d 2154.27 168.59 2034.93 84.30 1783.43 122.90 
AUMC0-inf ng/mL × d
2
 55368.12 6867.65 72221.99 7226.35 78541.27 9376.64 
MRT0-inf d 25.64 1.38 35.42 2.41 43.98 3.25 
Vz/F (mg)/(ng/mL) 0.14 0.01 0.41 0.03 0.46 0.05 
Cl/F 
(mg)/(ng/mL)/
d 
0.03 0.00 0.03 0.00 0.03 0.00 
Where t1/2 is half life, Tmax is time for maximum concentration, Cmax is maximum plasma concentration, 
AUC is area under plasma vs time curve, AUMC area under mean plasma vs time curve, MRT is maximum 
residence time, Vz/F is apparent volume of distribution, Cl/F is apparent clearance, d=days and S.D is 
standard deviation.  
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5. Conclusions 
Olanzapine loaded PLGA microspheres were successfully developed using solvent 
evaporation method. Formulations were prepared with sufficient encapsulation efficiency 
and yield. The properties of PLGA and other formulation parameters had significant 
impact on in vitro and in vivo release of drug from microspheres. In vitro and in vivo data 
indicates that microsphere formulations developed with PLGA (75:25) and PLGA (85:15) 
have provided a sufficient steady release of drug for at least 30 days; therefore these 
formulations can be potential candidates for 30 day depot injection drug delivery of 
olanzapine.  
Olanzapine loaded PNA microgels were successfully prepared with drug loading 
efficiency of 2.14 ± 0.52%. The nature in viscosity variation make this formulation 
favorable for injection from, as at pH 5.0, injection will not turn into gel on room 
temperature or even at higher temperatures. In vitro release was characterized by a high 
initial burst release up to 38.6% of the drug release within two hours. This high initial 
burst release indicates that this dosage form might not be suitable for injectable dosage 
form due to potential of producing toxic effects. In vivo release data indicates an initial 
high burst release from the subcutaneous injection of PNA microgels but this initial burst 
release was followed by a sustained release for 72 hours PNA microgels can be 
formulated for short term depot injection, which can potentially provide the release of 
olanzapine for 72 hours.  
In this study a PLGA based olanzapine in situ gel implant was successfully prepared 
using solvent exchange principle. In vitro and in vivo release data indicates that in situ gel 
implant has a tolerable initial burst release and a sustained release pattern extended to one 
month or more. Current PLGA based olanzapine in situ gel implant can be formulated as 
a potential candidate for depot injection in the treatment of schizophrenia for 30 days 
release.  
Olanzapine loaded PLGA based surgically implantable cylinders were successfully 
prepared using solvent extrusion method. Implants prepared with solvent extrusion had 
smooth surface and high entrapment efficiency. Ratio of lactide to glycolide in PLGA and 
initial drug loading had significant impact on the in vitro and in vivo release pattern of 
olanzapine from implants. In vitro and in vivo release studies indicate that this surgically 
implantable drug delivery system based on PLGA can release the drug for more than 70 
days.  
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